PLOS

ONE

Editorial Board

The *PLOS ONE* Editorial Board is powered by thousands of academic experts from all over the world. Our board comprises working scientists who are established principal investigators/group leaders with extensive publication records.

Academic Editors oversee the peer review process for the journal, including evaluating submissions, selecting reviewers and assessing their comments, and making editorial decisions. Together with fellow Editorial Board Members and internal staff, Academic Editors uphold journal policies and ethics standards and work to promote the *PLOS ONE* mission to provide free public access to scientific research.

Editorial board members affiliated with the Centers for Disease Control and Prevention are serving in a personal capacity. The views expressed are their own and do not necessarily represent the views of the Centers for Disease Control and Prevention or the United States Government.

Editorial board members affiliated with the World Health Organization are serving in a personal capacity. The views expressed are their own and do not necessarily represent the decisions, policy or views of the World Health Organization.

Interested in serving on the Editorial Board?

PLOS welcomes volunteers to the Editorial Board who support our mission, values, and commitment to providing a high-quality experience for our authors. Explore the Academic Editor role and apply online.

Academic Editors

To find a member, browse the list, search by name, or search by Section or Keyword. To search for multiple sections or keywords, enter a comma-separated list of terms.

The list of Academic Editors is updated weekly. If you are an Editorial Board member and would like to update any of the information below, please contact plosone@plos.org

Search for: [   ] [Search]

Displaying 1-50 of 9765 Editors.

Katriina Aalto-Setala
University of Tampere
FINLAND
Sections: Developmental biology - Cell differentiation; Cell fate determination; Stem cells; Embryology; Fertilization
Keywords: Biology and life sciences, Cellular types, Stem cells, Induced pluripotent stem cells, Embryonic stem cells, Developmental biology, Cell differentiation, Genetics, Genetics of disease, Genetic testing, Human genetics, Genetic association studies, Molecular genetics, Cardiovascular anatomy, Electrophysiology, Medicine and health sciences, Cardiology, Arrhythmia, Clinical genetics, Personalized medicine, Animal models, Mouse models, Model organisms

Mohd Nadhir Ab Wahab
ⓘ orcid.org/0000-0002-3549-6443
Universiti Sains Malaysia
MALAYSIA
Sections: Computer and information sciences - Artificial intelligence, machine learning and data science, Engineering and technology - Aerospace and automotive engineering, Robotics
Keywords: Computer and information sciences, Artificial intelligence, Real time computing, Engineering and technology, Mechanical engineering, Robotics, Robotics systems, Nanorobotics, Navigation, Optimization

Nurul Hidayah Ab Rahman
Universiti Tun Hussein Onn Malaysia
MALAYSIA
Sections: Computer and information sciences - Cryptography and computer security
Keywords: Computer and information sciences, Computing systems, Digital computing, Information technology, Computer security, Computing methods, Cloud computing

Nidaa Ababneh
ⓘ orcid.org/0000-0002-2155-3013
University of Jordan
JORDAN
Sections: Genetics - Mutation; Genetics of disease; Heredity, Stem cells and regenerative medicine, Neuroscience - Neurodegenerative diseases and dementia
Keywords: Medicine and health sciences, Neurology

Ukachukwu Okoroafor Abaraogu
ⓘ orcid.org/0000-0002-1967-1459
Glasgow Caledonian University
UNITED KINGDOM
Sections: Physiotherapy, Health care - Health services research, Cardiovascular science and medicine - Vascular diseases
Keywords: Medicine and health sciences, Health care, Cardiology, Cardiovascular medicine, Rehabilitation medicine, Vascular medicine, Complementary and alternative medicine

Francisco Martinez-Abarca
Estacion Experimental del Zaidin - CSIC
SPAIN

Sections: Agriculture - General
Keywords: Biology and life sciences, Genome evolution, Comparative genomics, Microbial ecology, Evolutionary biology, Transposable elements, Genomics, Metagenomics, Microbiology, Plant microbiology, Genome sequencing, Biochemistry, Nucleic acids, Biotechnology, Applied microbiology

Behnam Abasht
orcid.org/0000-0003-2374-8145
University of Delaware
UNITED STATES
Sections: Agriculture - Animals, Genetics - Gene function, Genomics
Keywords: Biology and life sciences, Agriculture, Livestock, Genetics

Abdul Qader Abbady
orcid.org/0000-0002-3898-5269
Atomic Energy Commission of Syria
SYRIAN ARAB REPUBLIC
Sections: Biotechnology - Genetic engineering, Immunology - General, Infectious diseases - General
Keywords: Biology and life sciences, Immunology, Microbiology, Virology, Molecular biology, Molecular biology techniques, Molecular biology assays and analysis techniques, Molecular biology display techniques, Phage display, DNA construction, DNA manipulations, Recombinant DNA technology, Organisms, Eukaryota, Protozoans, Parasitic protozoans, Leishmania, Biochemistry, Hormones, Peptide hormones, Growth hormone, Proteins, Conjugated proteins, Immune system proteins, Antibodies, Antigens, Protein interactions, Protein-lipid interactions, Protein-protein interactions, Protein structure, Protein folding, Recombinant proteins, Biomacromolecule-ligand interactions, Medicine and health sciences, Medical conditions, Infectious diseases, Zoonoses, Infectious disease control, Vaccines, Recombinant vaccines, Parasitic diseases, Protozoan infections, Leishmaniasis, Research and analysis methods, Molecular biology techniques, Precipitation techniques, Purification techniques, Protein purification

Cristiana Abbafati
orcid.org/0000-0003-2811-6251
Sapienza University of Rome
ITALY
Sections: Economics - Health economics, Health care - General, Public health and epidemiology - Health policies, systems and management
Keywords: Social sciences, Economics, Health education and awareness

Faisal Abbas
orcid.org/0000-0002-9312-5659
National University of Sciences and Technology
PAKISTAN
Sections: Economics - Health economics, Public health and epidemiology - Global health, Public health and epidemiology - Health policies, systems and management
Keywords: Nutrition, Malnutrition, Social sciences, Economics, Economic history, Development economics, Economic development, Economic analysis

Qaiser Abbas
Ghazi University
PAKISTAN
Sections: Agriculture - General, Economics - General, Economics - Health economics
Keywords: Agricultural economics, Ecology, Ecological economics, Neuroeconomics, Behavioral economics, Social sciences, Economics, Economic history, Economic models, Experimental economics, Labor economics, Resource management, Development economics, Economic analysis, Soil science, Ecology and environmental sciences, Environmental impacts, Environmental management, Natural resources, Environmental protection, Environmental economics, Health economics

Mahdieh Abbasalizad Farhangi
orcid.org/0000-0002-7036-6900
Tabriz University of Medical Sciences
IRAN, ISLAMIC REPUBLIC OF
Sections: Nutrition, Cardiovascular science and medicine - Arrhythmias and cardiac electrophysiology, Health care - Health education
Keywords: Biology and life sciences, Genetics, Immunology, Neuroscience, Nutrition, Diet, Malnutrition, Nutrients, Nutritional deficiencies, Nutritional diseases, Nutritiona disorders, Physiology, Medicine and health sciences, Endocrinology, Epidemiology, Cardiovascular medicine, Pharmacology, Drug research and development, Women's health, Clinical trials, Complementary and alternative medicine

Alireza Abbasi
orcid.org/0000-0001-9136-1837
UNSW
AUSTRALIA
Sections: Computer and information sciences - Artificial intelligence, machine learning and data science, Complexity and networks
Keywords: Computer and information sciences, Library science, Network analysis, Social networks, Social media

Mahdi Abbasi
orcid.org/0000-0002-5373-5778
Bu-Ali Sina University: Bu Ali Sina University
IRAN, ISLAMIC REPUBLIC OF
Sections: Computer and information sciences - Artificial intelligence, machine learning and data science, Computer and information sciences - Computer Hardware, Computer and information sciences - General
Keywords: Computer and information sciences, Artificial intelligence, Artificial neural networks, Expert systems, Genetic programming, Machine learning, Computing systems, Digital computing, Digital imaging, Network analysis, Network theory, Signaling networks, Network control, Neural networks, Feedforward neural networks, Recurrent neural networks, Random number generators, Real time computing, Computer applications, Computer architecture, Computer hardware, Microprocessors, Computer networks, Internet, Internet of Things, Computer vision, Computers, Computing methods

A. M. Abd El-Aty
orcid.org/0000-0001-6596-7907
Cairo University
EGYPT
Sections: Veterinary science, Pharmacology, Food science and technology
Keywords: Antimicrobials, Phytochemicals, Environmental chemistry, Medicine and health sciences, Pharmacology, Drugs, Pharmacodynamics, Pharmacogenetics, Pharmacokinetics, Pharmacologic analysis, Pharmacokinetic analysis, Drug interactions, Drug-food interactions, Physical sciences, Chemistry, Analytical chemistry,

Chemical analysis, Water analysis, Liquid chromatography-tandem mass spectrometry, Phytochemistry, Phytopharmacology, Research and analysis methods, Extraction techniques, Supercritical fluid extraction, Liquid-liquid extraction, Solid-phase extraction, Chromatographic techniques, Liquid chromatography

Yasmina Abd-Elhakim
ⓘ orcid.org/0000-0002-3646-6385
Zagazig University
EGYPT
Sections: Pharmacology, Pollution research and control, Toxicology
Keywords: Biology and life sciences, Agriculture, Toxicology, Veterinary science, Aquatic environments, Ecology and environmental sciences, Medicine and health sciences, Immunology, Pharmaceutics, Pharmacology, Research and analysis methods, Animal studies, Chromatographic techniques

Ashraf B. Abdel-Naim
King Abdulaziz University
SAUDI ARABIA
Sections: Pharmacology, Toxicology, Biochemistry - General
Keywords: Biology and life sciences, Rheumatoid arthritis, Toxicology, Oxidative damage, Medicine and health sciences, Basic cancer research, Cancer treatment, Cardiovascular pharmacology, Clinical pharmacology, Drug research and development, Clinical medicine, Complementary and alternative medicine, Animal models, Mouse models

Ahmed S. Abdel-Moneim
ⓘ orcid.org/0000-0002-3148-6782
Taif University
SAUDI ARABIA
Sections: Virology, Infectious diseases - Viral diseases, Microbiology - Virology
Keywords: Biology and life sciences, Viral evolution, Viral genetics, Microbiology, Virology, Emerging viral diseases, Viral disease diagnosis, Medical microbiology, Microbial pathogens, Viral pathogens, Orthomyxoviruses, Influenza viruses, Coronaviruses, SARS coronavirus, Avian influenza, Medicine and health sciences, Infectious diseases, Respiratory infections, Viral diseases, Influenza, SARS, Zoonoses, Pathology and laboratory medicine, Pathogens, Pulmonology

Muhammad Tarek Abdel Ghafar
ⓘ orcid.org/0000-0002-0621-4291
Tanta University Faculty of Medicine
EGYPT
Sections: Cancer - Biomarkers, molecular diagnostics and screening, Cancer - Immunotherapy and tumor immunology, Genetics - Gene expression; Epigenetics; Alternative splicing; RNA splicing; Molecular genetics
Keywords: Medicine and health sciences, Endocrinology, Epidemiology, Biomarker epidemiology, Genetic epidemiology, Molecular epidemiology, Cancer epidemiology, Hematology, Immunology, Autoimmunity, Clinical immunology, Genetics of the immune system, Oncology, Cancer risk factors, Genetic causes of cancer, Pathology and laboratory medicine, Clinical genetics, Clinical medicine, Diagnostic medicine

Muhammad Abdel-Gawad
ⓘ orcid.org/0000-0002-0204-4715
Al-Azhar University
EGYPT
Sections: Gastroenterology and hepatology, Infectious diseases - Hepatitis
Keywords: Medicine and health sciences, Gastroenterology and hepatology, Enteropathies, Gastroesophageal reflux disease, Gastrointestinal cancers, Gastrointestinal infections, Dysentery, Hepatomegaly, Hepatosplenomegaly, Inflammatory bowel disease, Colitis, Crohn's disease, Liver diseases, Acute liver failure, Liver disease and pregnancy, Liver fibrosis, Nonalcoholic steatohepatitis, Portal hypertension, Wilson's disease, Alcoholic liver disease, Autoimmune hepatitis, Chronic liver disease, Cirrhosis, Fatty liver, Hemochromatosis, Hepatocellular carcinoma, Infectious hepatitis, Liver function tests, Megacolon, Pancreatitis, Peptic ulcer disease, Splenomegaly, Zollinger-Ellison syndrome, Ascites, Barrett's esophagus, Biliary disorders, Cholecystitis and biliary colic, Cholelithiasis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Celiac disease, Constipation, Diarrhea

Walid Kamal Abdelbasset
ⓘ orcid.org/0000-0003-4703-661X
Prince Sattam Bin Abdulaziz University, College of Applied Medical Sciences
SAUDI ARABIA
Sections: Physiotherapy
Keywords: Sports and exercise medicine, Medicine and health sciences, Geriatrics, Health care, Metabolic disorders, Cardiology, Pain management, Pediatrics, Pulmonology, Rehabilitation medicine

Fadia Ahmed Abdelkader Reshia
ⓘ orcid.org/0000-0003-1838-595X
College of Applied Medical Sciences, Jouf University
SAUDI ARABIA
Sections: Cancer - Basic cancer research, Nursing, Psychology - General
Keywords: Birth weight, Educational attainment, Human families, Psychological stress, Fear, Nursing science, Patients, COVID 19, Depression, Critical care and emergency medicine, Triage, Nurses

Elsayed Abdelkreem
ⓘ orcid.org/0000-0002-8976-2989
Sohag University Faculty of Medicine
EGYPT
Sections: Pediatrics, Genetics - Mutation; Genetics of disease; Heredity, Clinical trials
Keywords: Cystic fibrosis, Medicine and health sciences, Child abuse, Neonatal care, Pediatric critical care, Metabolic disorders, Inborn errors of metabolism, Congenital disorders, Developmental and pediatric neurology, Pediatrics, Neonatology, Clinical genetics, Chromosomal disorders, Genetic diseases, Autosomal recessive diseases, Phenylketonuria, Sickle cell disease, Tay-Sachs disease, Wilson's disease, Congenital adrenal hyperplasia, Galactosemia, Gaucher's disease, Glycogen storage diseases, Mucopolysaccharidoses, Niemann-Pick disease

Zaid Abdo
ⓘ orcid.org/0000-0002-8272-7734
Colorado State University
UNITED STATES
Sections: Computational biology - Proteomics; Systems biology

Keywords: Biology and life sciences, Computational biology, Ecosystem modeling, Evolutionary modeling, Ecosystems, Ecosystem functioning, Microbial ecology, Spatial and landscape ecology, Systems ecology, Biota, Coastal ecology, Community ecology, Community assembly, Community structure, Evolutionary biology, Evolutionary genetics, Evolutionary processes, Parallel evolution, Evolutionary adaptation, Evolutionary systematics, Phylogenetics, Mutation, Marine biology, Microbiology, Bacteriology, Bacterial taxonomy, Biotechnology, Applied microbiology, Environmental biotechnology, Computer and information sciences, Software engineering, Software design, Computer modeling, Marine environments, Ecology and environmental sciences, Mathematics, Probability theory, Bayes theorem, Statistics, Biostatistics, Statistical methods

Mohammed S. Abdo
Hodeidah University
YEMEN
Sections: Mathematics - Applied mathematics
Keywords: COVID 19, Tuberculosis, Nonlinear systems, System stability, Fractional calculus, Integrals, Differential equations, Fractals, Mathematical and statistical techniques, Forecasting, Mathematical models, Mathematical modeling

Tahirou Abdoulaye
orcid.org/0000-0002-8072-1363
International Institute of Tropical Agriculture
NIGERIA
Sections: Agriculture - Plants, Economics - Econometrics, Economics - General
Keywords: Biology and life sciences, Agriculture, Agricultural economics, Social sciences, Economics

Roswanira Abdul Wahab
orcid.org/0000-0002-9982-6587
Universiti Teknologi Malaysia
MALAYSIA
Sections: Biotechnology - General, Chemistry - Multidisciplinary, Materials science - Nanomaterials and nanotechnology
Keywords: Biology and life sciences, Biochemistry, Biotechnology, Engineering and technology, Nanotechnology, Chemical engineering, Physical sciences, Chemistry, Materials science

Albiruni Abdul Razak
Princess Margaret Cancer Centre
CANADA
Sections: Cancer - Immunotherapy and tumor immunology, Clinical trials, Drug discovery
Keywords: Cancer immunotherapy, Antibody therapy, Medicine and health sciences, Oncology, Cancer treatment, Antiangiogenesis therapy, Oncolytic viruses, Cancers and neoplasms, Sarcoma, Clinical oncology, Cancer chemotherapy, Clinical trials (cancer treatment)

Syed Sharizman Syed Abdul Rahim
orcid.org/0000-0002-9090-2563
Universiti Malaysia Sabah
MALAYSIA
Sections: Public health and epidemiology - General, Public health and epidemiology - Chronic diseases, Infectious diseases - Epidemiology and prevention
Keywords: Vaccination and immunization, Disease vectors, Medicine and health sciences, Epidemiology, Infectious disease epidemiology, Molecular epidemiology, Cancer epidemiology, Natural history of disease, Spatial epidemiology, Disease dynamics, Disease surveillance, Socioeconomic aspects of health, Infectious diseases, Bacterial diseases, Tuberculosis, Vector-borne diseases, Viral diseases, Zoonoses, Emerging infectious diseases, Foodborne diseases, Infectious disease control, Parasitic diseases, Malaria, Elephantiasis, Helminth infections, Tropical diseases, Neglected tropical diseases, Public and occupational health, Preventive medicine

Anwar P.P. Abdul Majeed
orcid.org/0000-0002-3094-5596
Universiti Malaysia Pahang
MALAYSIA
Sections: Computer and information sciences - Artificial intelligence, machine learning and data science, Engineering and technology - Systems science and computational engineering, Robotics
Keywords: Computer and information sciences, Artificial intelligence, Neural networks, Engineering and technology, Mechanical engineering, Robotics

Afnizanfaizal Abdullah
orcid.org/0000-0002-0280-565X
University of Technology Malaysia: Universiti Teknologi Malaysia
MALAYSIA
Sections: Computational biology - Proteomics; Systems biology, Computer and information sciences - Artificial intelligence, machine learning and data science, Synthetic biology
Keywords: Biology and life sciences, Computational biology, Genome analysis, Genome expression analysis, Synthetic biology, Systems biology, Biochemical simulations, Computer and information sciences, Artificial intelligence, Machine learning, Machine learning algorithms, Signaling networks, Metabolic networks, Nonlinear dynamics, Computer modeling, Computerized simulations, Computing methods, Mathematical computing, Mathematics, Algorithms, Research and analysis methods, Microarrays, Simulation and modeling

Khatijah Lim Abdullah
orcid.org/0000-0002-7185-6004
Sunway University
MALAYSIA
Sections: Health care - Health education, Health care - Health services research, Health care - General
Keywords: Medicine and health sciences, Health care, Health care policy, Palliative care

Bawadi Abdullah
orcid.org/0000-0002-5908-5876
Universiti Teknologi Petronas
MALAYSIA
Sections: Engineering and technology - General
Keywords: Engineering and technology, Nanotechnology, Quantum dots, Nanomaterials, Chemical engineering, Energy and power, Bioenergy, Biofuels, Fuels, Hydrogen storage, Environmental engineering, Carbon sequestration

Mohammad Farris Iman Leong Bin Abdullah

 orcid.org/0000-0002-7762-4052

USM Advanced Medical and Dental Institute: Universiti Sains Malaysia Institut Perubatan dan Pengigian Termaju

MALAYSIA

Sections: Mental health and psychiatry - General, Psychology - Clinical psychology, Psychology - General

Keywords: Psychological stress, Medicine and health sciences, Metabolic disorders, Dyslipidemia, Mental health and psychiatry, Mood disorders, Neuropsychiatric disorders, Neuroses, Substance-related disorders, Cardiovascular medicine, Cardiovascular diseases

Johari Yap Abdullah

 orcid.org/0000-0002-6147-4192

Universiti Sains Malaysia

MALAYSIA

Sections: Computational biology - General, Dentistry and oral health, Neuroscience - Neuroimaging; Brain mapping

Keywords: Computer and information sciences, Artificial intelligence, Digital imaging, Computer vision, Medicine and health sciences, Radiology and imaging

Keiko Abe

The University of Tokyo

JAPAN

Sections: Cell biology - Cell signalling; Signal transduction

Keywords: Biology and life sciences, Signal transduction, Mechanisms of signal transduction, Signal termination, Cell signaling, Signaling cascades, Calcium signaling cascade, Calcium signaling, Computational biology, Genome analysis, Transcriptome analysis, Gene expression, Nervous system, Neural pathways, Neuroscience, Behavioral neuroscience, Sensory systems, Gustatory system, Sensory perception, Biochemistry, Neurochemistry, Neurochemicals, Proteins, Recombinant proteins, Biomacromolecule-ligand interactions, Genetic engineering, Transgenic engineering, Animal models, Mouse models, Model organisms, Microarrays

Takeru Abe

 orcid.org/0000-0003-3496-1953

Yokohama City University

JAPAN

Sections: Critical care and emergency medicine

Keywords: Medicine and health sciences, Epidemiology, Social epidemiology, Mental health and psychiatry

Woldaregay Erku Abegaz

College of Health Sciences, School of Medicine, Abibas Ababa University

ETHIOPIA

Sections: Microbiology - Bacteriology, Microbiology - Virology, Microbiology - Host-pathogen interactions

Keywords: Antibodies, Nosocomial infections, Chikungunya infection, Bacterial pathogens, Staphylococcus aureus, HIV, Chikungunya virus, Antibiotics, Antimicrobial resistance, Vaccination and immunization, Ethiopia, Enzyme-linked immunoassays

Steven M. Abel

 orcid.org/0000-0003-0491-8647

University of Tennessee

UNITED STATES

Sections: Computational biology - Proteomics; Systems biology, Immunology - General

Keywords: Biology and life sciences, Biophysics, Biophysical simulations, Cell biology, Signal transduction, Immune cells, Computational biology, Gene regulatory networks, Immunology, Immune response, Lymphocyte activation, Theoretical biology, Immune receptors, Biochemical simulations, Cell mechanics, Physical sciences, Physics, Statistical mechanics

Pasquale Abete

Universita degli Studi di Napoli Federico II

ITALY

Sections: Geriatrics

Keywords: Cognitive impairment, Medicine and health sciences, Frailty, Cardiology, Arrhythmia, Atrial fibrillation, Heart failure, Cardiovascular diseases, Coronary heart disease, Vascular medicine, Hypertension, People and places, Population groupings, Age groups, Young adults

Javier Abián-Vicén

 orcid.org/0000-0001-9635-3289

University of Castilla-La Mancha

SPAIN

Sections: Sport and exercise science, Biomechanics

Keywords: Biology and life sciences, Sports science

Syed Hani Hassan Abidi

 orcid.org/0000-0001-9497-0902

Nazarbayev University School of Medicine

PAKISTAN

Sections: Microbiology - Host-pathogen interactions, Microbiology - Virology, Infectious diseases - Viral diseases

Keywords: Biology and life sciences, Computational biology, Genome evolution, Evolutionary modeling, Microbial evolution, Viral evolution, Immunology, Immune evasion, Antigen processing and recognition, Major histocompatibility complex, Microbiology, Microbial mutation, Virology, Emerging viral diseases, Medicine and health sciences, Co-infections, Oncology, Basic cancer research, Urology, Prostate diseases, Prostate cancer

Mohammad Reza Abidian

University of Houston

UNITED STATES

Sections: Biotechnology - Bioengineering

Keywords: Bioengineering, Biological systems engineering, Biomedical engineering, Biomimetics, Bionics, Tissue engineering, Engineering and technology

Shawky M Aboelhadid

 orcid.org/0000-0002-1403-2527

Beni Suef University Faculty of Veterinary Medicine

EGYPT

Sections: Veterinary science, Agriculture - Animals, Biotechnology - General

Keywords: Biology and life sciences, Molecular biology techniques, Artificial gene amplification and extension, Polymerase chain reaction, Ticks, Parasitology, Veterinary parasitology, Disease vectors, Veterinary science, Zoology, Animal diseases, Biotechnology, Medicine and health sciences, Infectious diseases, Foodborne diseases

Raymond Akawire Aborigo
ⓘ orcid.org/0000-0003-0642-9265
Navrongo Health Research Centre
GHANA
Sections: Public health and epidemiology - Global health, Public health and epidemiology - Health behavior, health promotion and society, Mental health and psychiatry - Biological
Keywords: Social sciences, Anthropology, Sociology, Sexual and gender issues, Female genital mutilation, Veteran care, Public and occupational health, Behavioral and social aspects of health, Global health, Women's health, Research and analysis methods, Research design, Case-control studies, Observational studies, Qualitative studies, Retrospective studies, Survey research, Census, Questionnaires, Survey methods, Surveys, Health surveys, Cohort studies

Wassim Abou-Kheir
ⓘ orcid.org/0000-0001-9719-9324
American University of Beirut
LEBANON
Sections: Cancer - Biomarkers, molecular diagnostics and screening, Cell biology - General
Keywords: Biology and life sciences, Cell biology, Molecular biology, Medicine and health sciences, Oncology

Abdelilah Aboussekhra
King Faisal Specialist Hospital and Research Center
SAUDI ARABIA
Sections: Cancer - Basic cancer research
Keywords: Biology and life sciences, Signal transduction, Cell signaling, Beta-catenin signaling, Signaling cascades, Protein kinase signaling cascade, AKT signaling cascade, Cell cycle and cell division, Cell death, Genetics, Gene expression, Gene regulation, Molecular genetics, Biochemistry, Nucleic acids, DNA, DNA repair, DNA modification, Medicine and health sciences, Oncology, Basic cancer research, Cancer treatment, Breast cancer, Obstetrics and gynecology, Model organisms, Yeast and fungal models

Thomas Abraham
ⓘ orcid.org/0000-0003-0750-8774
Pennsylvania State Hershey College of Medicine
UNITED STATES
Sections: Cell biology - Cell membranes; Vesicles; Cellular structures and organelles, Physics and astronomy - Optics and photonics
Keywords: Cell motility, Cell migration, Cancer cell migration, Directed cell migration, Cellular structures and organelles, Extracellular matrix, Pulmonary fibrosis, Optical imaging of intrinsic signals, Biomaterials, Cell mechanics, Tissue mechanics, Pulmonary imaging, Research and analysis methods, Microscopy, Scanning probe microscopy, Atomic force microscopy, Inverted microscopy, Light microscopy, Bright field microscopy, Polarized light microscopy, Two-photon excitation microscopy, Confocal microscopy, Confocal laser microscopy, Scanning confocal microscopy, Dark field microscopy, Fluorescence microscopy, Epifluorescence microscopy, Immunofluorescence microscopy, Optical microscopy

Lihi Adler-Abramovich
Tel-Aviv University
ISRAEL
Sections: Materials science - General
Keywords: Antibacterials, Peptide libraries, Biomimetics, Bionanotechnology, Nanomaterials, Drug delivery, Mechanical properties, Crystals, Gels, Surfactants, Crystal structure, Peptide synthesis

Yael Abreu-Villaça
ⓘ orcid.org/0000-0002-9801-6179
Universidade do Estado do Rio de Janeiro
BRAZIL
Sections: Neuroscience - Behavioral and cognitive, Neuroscience - Neural development and plasticity, Neuroscience - Neural systems and circuits
Keywords: Cell signaling, Developmental biology, Nervous system, Motor system, Neuroscience, Behavioral neuroscience, Synaptic plasticity, Developmental neuroscience, Learning and memory, Molecular neuroscience, Toxicology, Neurotoxicology, Biochemistry, Neurochemistry, Neuroendocrinology, Neurotransmitters, Mood disorders, Anxiety disorders, Animal models, Mouse models

Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island

June 18, 2021

Aakriti Pandita, Fizza S. Gillani, Yiyun Shi, Anna Hardesty, Meghan McCarthy, Jad Aridi, Dimitrios Farmakiotis, Silvia S. Chiang, Curt G. Beckwith

Background: In order for healthcare systems to prepare for future waves of COVID-19, an in-depth understanding of clinical predictors is...

Image credit

An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

June 18, 2021

Purwati, Andang Miatmoko, Nasronudin, Eryk Hendrianto, Deya Karsari, Aristika Dinaryanti, Nora Ertanti, Igo Syaiful Ihsan, Disca Sandyakala Purnama, Tri Pudy Asmarawati, Erika Marfiani, Yulistiani, Alfian Nur Rosyid, Prastuti Asta Wulaningrum, Herley Windo Setiawan, Imam Siswanto, Ni Nyoman Tri Puspaningsih

A potent therapy for the infectious coronavirus disease COVID-19 is urgently required with, at the time of writing, research in this area...

Image credit

Association of the past epidemic of *Mycobacterium tuberculosis* with mortality and incidence of COVID-19

PLOS ONE

RESEARCH ARTICLE

An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

Purwati[1,2,3]*, Andang Miatmoko[1,4], Nasronudin[5], Eryk Hendrianto[1], Deya Karsari[1], Aristika Dinaryanti[1], Nora Ertanti[1], Igo Syaiful Ihsan[1], Disca Sandyakala Purnama[1], Tri Pudy Asmarawati[5], Erika Marfiani[5], Yulistiani[4,5], Alfian Nur Rosyid[5], Prastuti Asta Wulaningrum[5], Herley Windo Setiawan[5], Imam Siswanto[6], Ni Nyoman Tri Puspaningsih[7]

1 Stem Cell Research and Development Center, Institute of Tropical Disease, Universitas Airlangga, Mulyorejo, Surabaya, Indonesia, 2 Faculty of Vocations, Universitas Airlangga, Gubeng, Surabaya, Indonesia, 3 Department of Biotechnology, Asia University, Wufeng, Taichung, Taiwan, 4 Faculty of Pharmacy, Universitas Airlangga, Mulyorejo, Surabaya, Indonesia, 5 Rumah Sakit Umum dan Rumah Sakit Khusus Infeksi, Universitas Airlangga, Mulyorejo, Surabaya, Indonesia, 6 Bioinformatic Laboratory, UCoE Research Center for Bio-Molecule Engineering Universitas Airlangga, Surabaya, Indonesia, 7 Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia

* purwati@fk.unair.ac.id

Abstract

A potent therapy for the infectious coronavirus disease COVID-19 is urgently required with, at the time of writing, research in this area still ongoing. This study aims to evaluate the in vitro anti-viral activities of combinations of certain commercially available drugs that have recently formed part of COVID-19 therapy. Dual combinatory drugs, namely; Lopinavir-Ritonavir (LOPIRITO)-Clarithromycin (CLA), LOPIRITO-Azithromycin (AZI), LOPIRITO-Doxycycline (DOXY), Hydroxychloroquine (HCQ)-AZI, HCQ-DOXY, Favipiravir (FAVI)-AZI, HCQ-FAVI, and HCQ-LOPIRITO, were prepared. These drugs were mixed at specific ratios and evaluated for their safe use based on the cytotoxicity concentration (CC_{50}) values of human umbilical cord mesenchymal stem cells. The anti-viral efficacy of these combinations in relation to Vero cells infected with SARS-CoV-2 virus isolated from a patient in Universitas Airlangga hospital, Surabaya, Indonesia and evaluated for IC_{50} 24, 48, and 72 hours after viral inoculation was subsequently determined. Observation of the viral load in qRT-PCR was undertaken, the results of which indicated the absence of high levels of cytotoxicity in any samples and that dual combinatory drugs produced lower cytotoxicity than single drugs. In addition, these combinations demonstrated considerable effectiveness in reducing the copy number of the virus at 48 and 72 hours, while even at 24 hours, post-drug incubation resulted in low IC_{50} values. Most combination drugs reduced pro-inflammatory markers, i.e. IL-6 and TNF-α, while increasing the anti-inflammatory response of IL-10. According to these results, the descending order of effective dual combinatory drugs is one of

LOPIRITO-AZI>LOPIRITO-DOXY>HCQ-AZI>HCQ-FAVI>LOPIRITO-CLA>HCQ-DOX. It
can be suggested that dual combinatory drugs, e.g. LOPIRITO-AZI, can potentially be used
in the treatment of COVID-19 infectious diseases.

Introduction

At the end of 2019, a case of pneumonia was diagnosed on the basis of a viral infection in
Wuhan, China [1]. The pathogen was identified as a novel enveloped RNA betacoronavirus2,
currently referred to as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
which has a phylogenetic similar to SARS-CoV. Since that time, it has developed into a global
pandemic due to Coronavirus SARS-CoV-2, also referred to as COVID-19 [2, 3]. On March
2nd 2020, the Indonesian Ministry of Health reported the first confirmed domestic positive
case of SARS-CoV-2. By September 2020, more than 262,000 individuals had been infected
with 10,105 cases culminating in death [4].

COVID-19 infection causes severe pneumonia with symptoms such as fever, a persistent
cough, and progressive breathing failure associated with respiratory complications. The high
hospitalization rate, risk of mortality and lack of a specific established treatment rendered
urgent the need for an effective therapy for COVID-19 to be developed. The main viral pro-
teinase has recently been considered positively as a suitable target for drug design against
COVID-19 infection due to its vital role in the poly-protein processing necessary for coronavi-
rus reproduction [5].

The term 'antiviral agents' refers to the medications prescribed to combat Middle East
Respiratory Syndrome (MERS) and SARS pandemics. Interferon α (IFN-α), lopinavir-ritonavir,
chloroquine phosphate, ribavirin, and Arbidol have been highlighted in the latest version of the
Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumo-
nia issued by the Republic of China's National Health Commission (NHC) as potential treatments
for COVID-19 [6]. In addition to antiviral agents, antibiotics such as amoxicillin, azithromycin or
fluoroquinolones are also being employed [7] in an attempt to eradicate the SARS-CoV-2 virus.
However, given the continuing lack of data regarding their efficacy as a form of COVID-19 ther-
apy, this study aims to evaluate the use of dual combinatory drugs as an antiviral therapy against
the SARS-CoV-2 virus, specifically COVID-19, within the Indonesian context.

During the present research, the respective in vitro antiviral activities of Lopinavir-Ritona-
vir (LOPIRITO), Favipiravir (FAVI), Azithromycin (AZI), Clarithromycin (CLA), Doxycy-
cline (DOXY), and Hydroxychloroquine (HCQ) as dual combinatory drugs at determined
ratios were analyzed. These ratios were established based on the plasma concentration of drugs
administered at the usual dose during clinical therapy, (see Table 1). However, in many cases,

Table 1. Peak plasma concentration of Lopinavir/Ritonavir (LOPIRITO), Azithromycin (AZI), Clarithromycin (CLA), Doxycycline (DOXY), Hydroxychloroquine (HCQ), and Favipiravir (FAVI) after a single oral administration of the drug.

Drugs	Dosage	Peak Plasma Concentration	Reference
Lopinavir/Ritonavir	Oral administration of Aluvia® tablet containing 400/100 mg Lopinavir/Ritonavir twice a day	Lopinavir: 6.9 to 17.7 μg/mL	[8]
Azithromycin	Single oral administration of 500 mg Azithromycin	0.35–0.45 mg/L after	[9]
Clarithromycin	oral administration of 250 and 500 mg Clarithromycin twice a day	1 and 2.41 μg/mL, respectively	[10]
Doxycycline	Single oral administration of 200 mg doxycycline	1.5 to 7.0 μg/ml after oral administration	[11]
Hydroxychloroquine	Single oral administration of 400 mg HCQ sulfate	0.28 to 0.54 μg/mL	[12]
Favipiravir	1600/600 mg twice a day	64.56 μg/mL	[13]

https://doi.org/10.1371/journal.pone.0252302.t001

there were limited or even no reports regarding the pharmacokinetic profiles in dual drug combinations.

Lopinavir, Ritonavir, and Favipiravir have all been used as antiviral agents which act as virus protease inhibitors [8, 9]. Azithromycin is classified as a macrolide antibiotic which has been used extensively in the treatment of severe respiratory lower tract infections such as pneumonia. It can be employed for preventing secondary infection often resulting from viral infection, thereby avoiding a severe prognosis. Azithromycin has been reported to be an immune modulator and anti-inflammatory agent [10, 11], while also inhibiting virus replication and the cytopathic effect mediated by the Zika virus in Glial cell lines and astrocytes [14]. Moreover, the use of clarithromycin has been regarded in the same manner as that of Azithromycin. Clarithromycin demonstrates a high affinity with the protein target of HIV-1 protease in the molecular docking study which is superior to that of doxycycline due to high hydrophobicity and partition co-efficiency [15]. The combined application of Clarithromycin and antiviral agents, i.e. Oseltamivir or Zanamivir, increased systemic immunity while reducing rates of infection-related relapse in children infected with the influenza virus [16]. Doxycyline, a tetracycline-derived drug, has an inhibitory effect on dengue fever viral replication and reduces the proinflammatory marker IL-6 during viral infections [17]. Consequently, it may prove effective as a form of COVID-19 therapy [18, 19]. Hydroxychloroquine is an aminoquinoline-derivate compound producing fewer severe side effects than chloroquine [20]. It has been employed as an antiviral agent [21, 22] which impedes the viral pre-entry stage, inhibits both viral replication mediated by acidic endocytosis and viral replication through modification of post-translation virus protein, hinders virus maturation via pH modulation, and produces anti-inflammatory effects by reducing IL-6 levels in serum [23].

In this present work, the efficacy of these drugs as a form of COVID-19 therapy was evaluated on Vero cells as viral hosts cultured with SARS-CoV-2 virus isolated from hospitalized patients in Universitas Airlangga Hospital, Surabaya, Indonesia. Furthermore, an analysis of the structure-based computational modelling of ligand-receptor interactions evaluated their potential use as the main protease of SARS-CoV-2 inhibitor [24].

Material and methods

Materials

Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore). All other reagents and solvents employed in this study were of the highest quality available. Milli-Q water was used in all experiments.

Virus and cell collection

Vero cells were used for virus inoculation against SARS-CoV-2 isolates in Indonesia. Cells were seeded in a 12-well microplate at a cell density of $5x10^4$ cells/well cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, USA) containing 10% foetal bovine serum (Gibco, USA), 1% penicillin-streptomycin (Gibco, USA) and 1% amphotericin-B (Gibco, USA). Cells were incubated in a CO_2 incubator at 37˚C in a humidified atmosphere of 5% CO_2 for 24 hours and cultured to reach 80–90% confluence.

SARS-CoV-2 virus isolates were collected from PCR-positive confirmed patients in Universitas Airlangga Hospital, Surabaya. Patient sputum sampling and clinical procedures were performed in accordance with the ethical clearance issued by The Ethics Commission of Universitas Airlangga Hospital (Certificate number 136/KEP/2020 dated April 20, 2020). The sputum of conscious patients was collected in viral transport medium (VTM) containing Gentamycin sulphate (100μg/ml) and Amphotericin B (0.5μg/ml). Further experiments were conducted in the Biosafety Level (BSL)-3 Laboratory at The Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia. In order to isolate the virus, the sputum samples were inserted into a new conical tube, subsequently vortexed for five minutes, and centrifuged at 13,000 rpm for ten minutes. After centrifugation, the supernatant of each sample was extracted for the purposes of further experiments.

Preparation of drugs solution

Each tablet containing drugs was triturated and mixed until homogenous. Approximately 50 mg equivalent mass of drugs were weighed and added to dimethyl sulfoxide in order to solubilize the drugs. The suspension was sonicated in a water bath for 15 minutes before being added to Rosewell Park Memorial Institute (RPMI) media, sonicated again and vortexed to mix it until homogenous. The suspension was then filtered through a polycarbonate membrane with a pore size of 0.45 μm and then a pore size of 0.22 μm under aseptic conditions. The filtrate was mixed with 10% foetal bovine serum and penicillin streptomycin before being vortexed to produce a homogenous mixture to be used as a stock solution. The samples were prepared by diluting the stock solution of each drug with RPMI complete media at an appropriate level of dilution to produce a determined concentration. The dual combinatory drugs mixtures were prepared by mixing appropriate amounts of two drug stock solutions in order to produce a final concentration at the required level. The combinatory drugs were evaluated at both constant and non-constant ratios to evaluate their effects on the cytotoxicity, including; antagonistic, synergistic, or additive. A constant ratio of the mixture was achieved by adding drug solutions at the same ratio, thereby increasing each drug concentration, to produce dose escalation. In contrast, at a non-constant ratio, a fixed determined concentration of drug was added to increased doses of other drug solution in order to produce different levels of drug concentration.

Cytotoxicity assay for dual combinatory drugs

The cytotoxic concentration (CC_{50}) of drugs was performed by means of MTT assay at the Stem Cell Research and Development Center, Universitas Airlangga using human umbilical cord mesenchymal stem cells which had been obtained from human placenta tissue as approved by the Ethical Committee of Universitas Airlangga Hospital (Certificate number 101/KEH/2019 dated January 10, 2019). The cells were prepared as the primary cell culture and used for the cytotoxicity assay because of their sensitivity to chemicals. Cells were seeded into 96-well microplates at a concentration of 1×10^3 cells/well in 100 μL Alpha Minimum Essentials Medium (α-MEM, Gibco, USA) supplemented with 10% foetal bovine serum, 1% penicillin-streptomycin and 1% amphotericin-B. The plates were then incubated in a CO_2 incubator at 37°C with 5% CO_2 for 24 hours, at which point, the supernatant was replaced with α-MEM containing drugs at each concentration and incubated for a further 48 hours. Approximately 25μL of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium-bromide (MTT) reagent at a concentration of 5mg/mL was subsequently added to each well and incubated for four hours at 37°C with 5% CO_2. Purple formazan crystals were formed and observed under an inverted microscope. Dimethyl sulfoxide was added to each well with the complete

solubilisation of formazan crystals subsequently being observed. The greater the number of formazan crystals formed, the lower the toxicity of the samples which were read for optical density of formazan using a multi reader at a measurement wavelength of 595 nm (Promega Glomax, USA). The CC_{50} value was analyzed by CompuSyn software (the ComboSyn Inc., accessed from www.combosyn.com).

Virus inoculation and antiviral assay for dual combinatory drugs

Vero cells obtained from Elabscience® (Catalog No. EP-CL-0242, USA) were seeded in a 12-well plate and confirmed as reaching 80–90% confluence on the day of virus inoculation. The culture medium was removed and the cells were then added to RPMI media containing SARS-CoV-2 isolates, previously diluted with RPMI media at a ratio of 1:2. In this study, about 2,000 virus copies were added to 50,000 cells of Vero cells, with a multiplicity of infection (MoI) degree of 0.04. The plate was gently agitated for 30 minutes and incubated at 37˚C, 5% CO_2 for 24 hours. About 3 mL of complete culture medium were subsequently added to the plate and incubated at 5% CO_2 37˚C for 24 hours, at which point 3 mL of RPMI media containing a drug combination were introduced and incubated at 5% CO_2 37˚C for 24, 48, and 72 hours. The drug mixtures were prepared at appropriate weight constant ratios selected on the basis of the optimum safety profiles in the cytotoxicity study. The Vero cells were observed post-treatment to observe the cytopathic effects, including; the rounding and detachment of cells. Moreover, the IC_{50} values were determined in order to quantify antiviral activity by measuring the proviral load in each well. The determination of the proviral load was performed by means of a Seegene COVID-19 detection Kit (Beijing, China) which detected three target genes, i.e. N-gene, E-gene and RdRP-gene. Amplification and data acquisition were carried out using the ABI Prism 7500 Sequence detector system (Applied Biosystems, USA). The IC_{50} value was further analyzed using CompuSyn software (The ComboSyn Inc., accessed from www.combosyn.com).

Measurement of IL-6, IL-10 and TNF-α levels of virus-infected Vero cells incubated with dual combinatory drugs

To enable measurement of IL-6, IL-10 and TNF-α levels, the culture medium of the treated cells was collected in sterile micro-tubes and centrifuged at 3,500 rpm for 20 minutes. The supernatants were carefully collected and diluted with aquadest at a 1:5 volume ratio and vortexed until homogenous. The samples were deposited onto a well-plate, added to ELISA reagents (Bioassay Technology Laboratory, Shanghai, China), and incubated at 37˚C for 60 minutes. Reagent substrate solution was then added to the well and incubated for ten minutes at 37˚C. The samples were measured for antigen concentration using the optical density (OD) plotted into the standard curves of IL-6, IL-10, and TNF-α.

Molecular docking study of drugs against main protease of SARS-CoV-2 virus

The molecular docking study was carried out by using Schrodinger Maestro 2019–2 Maestro software including protein preparation, ligand preparation, grid generation and receptor-ligand docking. The Linux operating system was used for the computational study. Ligands (Lopinavir, Ritonavir, Favipiravir, Azithromycin, Clarithromycin, Doxycycline, and Hydroxychloroquine) were downloaded from the NCBI (http://www.ncbi.nlm.nih.gov/pccompound). The crystal Structure of SARS-CoV-2 main protease, PDB ID: ALU6 was retrieved from the Protein Data Bank (PDB) (https://www.rcsb.org/).

The main protease protein was prepared for a docking study by using in Schrodinger 2019–2 Maestro software. All ligand compounds were prepared using LigPrep, which can produce low energy isomer of the ligand in optimization by using the OPLS_2005 force field. The OPLS_2005 force field was used for generating Grid on protein receptors. Schrodinger 2019–2 version was used to predict the binding affinity, ligand competence, and inhibitory candidate to the protein by performing rigid, flexible docking. The ligands were docked with generated Grid of receptor protein PDB ID: ALU6 The optimal ligand selection for the receptor was done based on the docking score.

Preparation of ligands and receptors. *Ligand-receptor complex.* The complex in the form of a crystal structure consisting of native ligands and receptors was downloaded from the Protein Data Bank (PDB) server at the web address https://www.rcsb.org with ID 6LU7 [25]. 6LU7 protein structure consists of two chains (A and C). The Main protease (Mpro) is in the A chain (shown in brown), while the native ligand appears as blue in the C chain, as presented in Fig 1.

The receptors and ligands from the resulting crystalline structure did not undergo geometric optimization treatment because they were obtained from the actual structure. For the purposes of the docking procedure, the ligands of this crystal were given a partial charge of the atom using the Austin Model 1 semi-empirical method with Bond Charge Correction (AM1-BCC) [26], while the receptor partial charge was calculated by means of a molecular mechanics approach with a force field of ff14SB [27].

Preparation of candidates as ligands. A sketch of the molecular structure of the ligand was produced using the ChemDraw Professional version 17 program. This structural sketch was still 2-dimensional with the result that a 3-dimensional structure had to be made. This structure was formed by calculations using the MM + molecular mechanics method to quickly obtain a 3-dimensional structure. The calculations were performed using a HyperChem 6 program. The structure of the calculation using the molecular mechanics method was then refined using a semi-empirical Parametric Model number 3 (PM3) quantum mechanics calculation. The calculations were completed using Gaussian 16 software. The partial atomic charge of each ligand was calculated through application of the AM1-BCC semi-empirical method.

Construction surface and receptor spheres. The receptor surface (molecular surface, ms) consisting of a number of cluster spheres was created and calculated using the dms module which is part of the Dock 6 program [28]. The active side of the M^{pro} was determined based on the native ligand position in the cluster. This active side location was used as the basis for the construction of the simulation box. The degree of margin for the formation of the simulation box was 10 Å.

Creating a simulation box. Depending on the position of the native ligand, a simulation box was built around it in the shape of a cube. The position of the simulation box, native ligand, and cluster of spheres relative to the receptor can be seen in the Fig 2.

Validation of docking parameters. The parameters to be employed in docking the candidate to the receptor were validated by redocking the native ligand to the receptor. An effective docking parameter must be able to return the native ligand to its original position with a maximum root mean square deviation (rmsd] tolerance of 2 Å [26]. The docking parameter validation resulted in an rmsd of 1.725 Å, indicating that use of the docking parameters at the docking stage for candidate ligands was feasible.

Results

Characterization of human umbilical cord mesenchymal stem cells

For the cytotoxicity assay of combinatory drugs, the primary cell cultures of human umbilical cord mesenchymal stem cells were used as the experimental cells. From the contents of Fig 3, it

Fig 1. Image representation of ligand-receptor complex.

is clear that, as previously reported [28–31], the stem cells were well differentiated as indicated by immunocytochemistry assays conducted using CD45, CD90, and CD105 antibodies.

Cytotoxicities of dual drug combination of LOPIRITO-AZI in mesenchymal stem cells

In this study, the cytotoxicity assay was evaluated for single and dual combinatory drugs during a period of 48 hours of drug incubation. This assay was intended to evaluate the toxicity of dual combinatory drugs on normal cells. The combination ratios were calculated taking into consideration the usual therapeutic doses and plasma peak concentrations of the drugs. To determine this cytotoxicity, the drugs were mixed at both constant and non-constant ratios.

Fig 2. The position of the simulation box, native ligand, and cluster of spheres relative to the receptor.

The evaluation of LOPIRITO and AZI in the stem cells showed that AZI had relatively non-toxic properties compared to those of LOPIRITO, while the CC_{50} values were $1.3x10^{55}$ µg/mL for AZI and $4.29x10^{2}$ µg/mL for LOPIRITO, as shown in Fig 4. The combination of LOPIRITO and AZI at constant weight ratios of 1:1 and 1:2 respectively, and non-constant ratios resulted in decreases in the degree of cytotoxicity. These were much safer than LOPIRITO as indicated by their higher CC_{50} values. These results indicate that a combination of both drugs negates the side effects of each single one, possibly producing an antagonist effect.'

Fig 3. Phase contrast and fluorescence images of human umbilical cord stem cells stained with anti-CD45, CD90, and CD105 antibody and CF555-labelled secondary antibody observed under a fluorescence microscope at a magnification of 100x.

https://doi.org/10.1371/journal.pone.0252302.g003

Cytotoxicities of dual drug combination of LOPIRITO-CLA in mesenchymal stem cells

The results of a cytotoxicity assay indicated that LOPIRITO was relatively more toxic to the cells than CLA as indicated by their CC_{50} values as a single drug which were 7.46×10^2 µg/mL and 2.28×10^3 µg/mL respectively, as shown in Fig 5. Moreover, the dual drug combination of LOPIRITO:CLA at the weight ratio of 1:1 had a high CC_{50} value of 1.22×10^4 µg/mL, indicating that this combination reduced the toxicity of both drugs in the stem cells.

Cytotoxicities of dual drug combination of LOPIRITO-DOXY in mesenchymal stem cells

Further evaluation was conducted for the dual combination of LOPIRITO and DOXY. The results showed that LOPIRITO has higher cytotoxicity than DOXY, as shown in Fig 6. The dual combination of LOPIRITO and DOXY, at both constant and non-constant ratios, resulted in significantly higher CC_{50} values (until undetected) than those of single drugs which were 3.45×10^3 µg/mL and 1.65×10^4 µg/mL respectively for LOPIRITO and DOXY. This indicated that these combinations reduced drug toxicity in the stem cells.

Cytotoxicities of dual drug combination of HCQ-AZI in mesenchymal stem cells

The cytotoxicity assay was also evaluated for dual combination of HCQ and AZI. As shown in Fig 7, HCQ produced higher cytotoxicity than AZI. Combining these drugs increased the CC_{50} values resulting in a lower toxic effect than that of HCQ. The dual combination drug at a ratio of 1:2 for HCQ and AZI produced the lowest cytotoxicity in the stem cells in which the CC_{50} was 2.81×10^4 µg/mL, thus providing for its potential use in an anti-viral study of COVID-19.

| Drug	CC$_{50}$ (µg/mL)
LOPIRITO	4.29×10^2
AZI	1.3×10^{55}
LOPIRITO:AZI (1:1, w/w)	1.56×10^4
LOPIRITO:AZI (1:2, w/w)	1.15×10^{10}
LOPIRITO 8 µg/mL + AZI	>408, ND
LOPIRITO + AZI 50 µg/mL	>450, ND

Fig 4. The cytotoxicity of Lopinavir-Ritonavir (LOPIRITO) and Azithromycin (AZI) as a single drug (left) and dual drug combination at constant and non-constant ratios (right) analysed by CompuSyn Software (n = 3). At non-constant ratios of LOPIRITO 8 µg/mL + AZI, LOPIRITO was added at a concentration of 8 µg/mL to each increased level of AZI, i.e. 0.2, 2, 10, 100, and 400 µg/mL. On the other hand, AZI was then added at a concentration of 50 µg/mL to each increased level of LOPIRITO, i.e. 0.2, 2, 10, 100, and 400 µg/mL to produce LOPIRITO + AZI 50 µg/mL.

Cytotoxicities of dual drug combination of HCQ-DOXY in mesenchymal stem cells

The use of HCQ was combined with DOXY to evaluate its safety when used during antiviral studies. As can be seen in Fig 8, HCQ had higher cytotoxicity than DOXY. Furthermore, the results showed that the dual drug combination produced lower toxicity in the stem cells than that of a single HCQ-based treatment. The CC$_{50}$ values of a combination of HCQ-DOXY at respective weight ratios of 1:1 and 1:2 were 4.37×10^3 µg/mL and 1.77×10^5 µg/mL, while the HCQ was 1.50×10^3 µg/mL.

Cytotoxicities of dual drug combination of FAVI-AZI in mesenchymal stem cells

The use of FAVI and AZI in an antiviral study of COVID-19 was initially evaluated for cyto-toxicity against primary cultured stem cells. As shown in Fig 9, the results indicated that both

| Drug	CC$_{50}$ (µg/mL)
LOPIRITO	7.46×10^2
CLA	2.28×10^3
LOPIRITO:CLA (1:1, w/w)	1.22×10^4
LOPIRITO:CLA(1:0.5, w/w)	1.05×10^3
LOPIRITO 8 µg/mL + CLA	>408, ND
LOPIRITO + CLA 1 µg/mL	>401, ND

Fig 5. The cytotoxicities of Lopinavir-Ritonavir (LOPIRITO) and Clarithromycin (CLA) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of LOPIRITO 8 µg/mL + CLA, LOPIRITO was added at a concentration of 8 µg/mL to each increased levels of CLA i.e. 0.2, 2, 10, 100, and 400 µg/mL. On the other hand, CLA was then added at a concentration of 1 µg/mL to each increased levels of LOPIRITO i.e. 0.2, 2, 10, 100, and 400 µg/mL to produce LOPIRITO + CLA 1 µg/mL.

FAVI and AZI, administered either as a single drug or in dual combination, produced very low cytotoxicity effects. It could be confirmed that FAVI and AZI were considered drugs not harmful to mesenchymal stem cells.

Cytotoxicities of dual drug combination of HCQ-FAVI in mesenchymal stem cells

The HCQ was also evaluated for its combination with FAVI. As presented in Fig 10, as a single drug, HCQ produced more intense cytotoxic effects in the mesenchymal stem cells than did FAVI whose CC$_{50}$ value of HCQ was 11.75 µg/mL. Combining HCQ with FAVI reduced the toxicity resulting in higher CC$_{50}$ values of the HCQ-FAVI combination which were 343 µg/mL and 954 µg/mL for HCQ-FAV mixed at the ratios of 1:5 and 1:10 respectively.

| Drug	CC_{50} (µg/mL)
LOPIRITO	3.45×10^3
DOXY	1.65×10^4
LOPIRITO:DOXY (1:1, w/w)	>800, ND
LOPIRITO:DOXY (1:2, w/w)	>1,200, ND
LOPIRITO 8 µg/mL + DOXY	>408, ND
LOPIRITO+ DOXY 2 µg/mL	>402, ND

Fig 6. The cytotoxicities of Lopinavir-Ritonavir (LOPIRITO) and Doxycycline (DOXY) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of LOPIRITO 8 µg/mL + DOXY, LOPIRITO was added at a concentration of 8 µg/mL to each increased levels of DOXY i.e. 0.2, 2, 10, 100, and 400 µg/mL. On the other hand, DOXY was then added at a concentration of 2 µg/mL to each increased levels of LOPIRITO i.e. 0.2, 2, 10, 100, and 400 µg/mL to produce LOPIRITO + DOXY 2 µg/mL.

https://doi.org/10.1371/journal.pone.0252302.g006

Cytotoxicities of dual drug combination of HCQ-LOPIRITO in mesenchymal stem cells

HCQ was dually combined with LOPIRITO and evaluated for its safe use against mesenchynal stem cells. In this assay, HCQ and LOPIRITO produced relatively low CC_{50} values of 2.51 and 58.55 µg/mL and were considered potentially toxic drugs and combinations as shown in Fig 11. The dual combination of HCQ and LOPIRITO produced higher CC_{50} values than single HCQ, i.e. 9.38 µg/mL and 8.45 µg/mL, for HCQ:LOPIRITO combined at weight ratios of 1:1 and 1:2. respectively. However, they were still more toxic than LOPIRITO.

Antiviral activity in Vero cells infected with SARS-CoV-2-isolated human virus

After cytotoxic evaluation of dual drug combination in mesenchymal stem cells, the drugs were subsequently assessed for antiviral activities against the SARS-CoV-2 virus isolated from

Fig 7. The cytotoxicities of Hydroxychloroquine (HCQ) and Azithromycin (AZI) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of HCQ + AZI 50 μg/mL, AZI was added at a concentration of 50 μg/mL to each increased levels of HCQ i.e. 0.2, 2, 10, 100, and 400 μg/mL. On the other hand, HCQ was then added at a concentration of 6 μg/mL to each increased levels of AZI i.e. 0.2, 2, 10, 100, and 400 μg/mL to produce HCQ 6 μg/mL + AZI.

patients in Universitas Airlangga Hospital. The Vero cells were inoculated with the virus which led to certain changes in their morphology indicating that the virus had successfully infected them. Fig 12 contains the typical formations of virus-infected cells observed at 24, 48, and 72 hours post-inoculation. At 24 hours post-inoculation, the presence of groups or colonies of detached cells indicated that they were dead. Furthermore, the formation of giant cells was observed in the 48 hours followed by a cytopathic effect clearly evident in the cells at 72 hours after the virus inoculation.

In addition to the photomicrographs of cell morphological changes, pro-viral load determination indicated that virus copy numbers had increased during the incubation period, as shown in Table 2.

The single drug and dual drug combination were added to the infected Vero cells and incubated for 24, 48 and 72 hours. The virus challenge test (IC_{50} in ppm) of single drug and drug combination against Vero cells infected with SARS-CoV-2 isolate, with a multiplicity of infection (MoI) value of 0.04, showed that combining drugs resulted in lower IC_{50} of each single drug than those of single drug uses. As can be seen in Table 3 and Figs 13 and 14, LOPIRITO +

Fig 8. The cytotoxicities of Hydroxychloroquine (HCQ) and Doxycycline (DOXY) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of HCQ + DOXY 2 μg/mL, DOXY was added at a concentration of 2 μg/mL to each increased levels of HCQ i.e. 0.2, 2, 10, 100, and 400 μg/mL. On the other hand, HCQ was then added at a concentration of 6 μg/mL to each increased levels of DOXY i.e. 0.2, 2, 10, 100, and 400 μg/mL to produce HCQ 6 μg/mL + DOXY.

AZI (1:2) resulted in an IC_{50} of less than 8.33 ppm for 24-hour incubation which was lower than those of single use LOPIRITO and AZI which were 12.10 and 51.90 μg/mL respectively. LOPIRITO + CLA (1:1) also produced a similar result at 24 hours post-incubation with a lower IC_{50} value, at 6.90 μg/mL, than those of single LOPIRITO and CLA at 12.10 and 4.60 μg/mL. A drug combination of LOPIRITO + DOXY (1:1) lowered the IC_{50} of DOXY at 24 hours after drug incubation, which was reduced from 18 μg/mL as a single drug to 13.94 μg/mL as a dual drug combination. On the other hand, the combination of HCQ with AZI, DOXY, FAVI, and LOPIRITO increased the IC_{50} values against their single drug uses, as well as the combination of FAVI + AZI (2:1).

On the other hand, the evaluation of each concentration of drug combination at a determined drug incubation period reveals that the use of drug combinations resulted in a lower drug concentration required for producing undetected virus numbers than the single drug uses, as evident from Table 4. The combination of LOPIRITO + AZI (1:2) composed of 13.4 μg/mL LOPIRITO and 33.6 μg/mL AZI had produced undetected virus numbers at 24, 48, and 72

Fig 9. The cytotoxicities of Favipiravir (FAVI) and Azithromycin (AZI) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of FAVI + AZI 50 μg/mL, AZI was added at a concentration of 50 μg/mL to each increased levels of FAVI i.e. 0.2, 2, 10, 100, and 400 μg/mL. On the other hand, FAVI was then added at a concentration of 66 μg/mL to each increased levels of AZI i.e. 0.2, 2, 10, 100, and 400 μg/mL to produce FAVI 66 μg/mL + AZI.

https://doi.org/10.1371/journal.pone.0252302.g009

hours post-incubation at a concentration of 50 μg/mL which were lower than the concentrations of each single drug required for generating a similar result, namely; 37.5 and 125 μg/mL for LOPIRITO and AZI respectively. This was also observed for a drug combination of LOPIRITO + CLA(1:1), LOPIRITO + DOXY (1:1), and HCQ + LOPIRITO (1:2). However, the combination of HCQ + AZI (1:2), HCQ + DOXY (1:2), FAVI + AZI (2:1), and HCQ + FAVI (1:10) produced no higher efficacy in respect of virus eradication than their single drugs.

IL-6, IL-10 and TNF-α levels of virus-infected Vero cells incubated with dual combinatory drugs

An analysis of pro-inflammatory and anti-inflammatory responses was further conducted included Interleukin-10 (IL-10), Interleukin-6 (IL-6), and Tumor Necrosis Factor-α (TNF-α). As shown in Table 5, the administration of LOPIRITO, AZI, CLA, and HCQ increased IL-10 levels and reduced the efficacy of IL-6 as a pro-inflammatory marker, but had no effects on

Fig 10. The cytotoxicities of Hydroxychloroquine (HCQ) and Favipiravir (FAVI) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of HCQ 6 µg/mL + FAVI, HCQ was added at a concentration of 66 µg/mL to each increased levels of FAVI i.e. 0.2, 2, 10, 100, and 400 µg/mL. On the other hand, FAVI was then added at a concentration of 66 µg/mL to each increased levels of HCQ i.e. 0.2, 2, 10, 100, and 400 µg/mL to produce HCQ + FAVI 66 µg/mL.

https://doi.org/10.1371/journal.pone.0252302.g010

TNF-α levels. However, for the most part, the use of dual drug administration increased IL-10 levels as an anti-inflammatory marker and reduced IL-6 and TNF-α levels as pro-inflammatory markers, but there were no noticeable effects on these interleukin levels for the FAVI + AZI (2:1) combination.

Molecular docking study of drugs against main protease of SARS-CoV-2 virus

By using an in silico method as shown in Fig 15, it can be seen that all the ligands including LOPIRITO, FAVI, AZI, CLA, DOXY, and HCQ can interact with the virus main protease with high docking scores ranging from -37.46 to -22.01 (see Table 6). DOXY recorded the lowest docking score, -37.46 kcal/mol and had a potency higher than Ritonavir (RITO). In contrast, AZI had the highest docking score of approximately -22.01 kcal/mol.

The parameters to validate the docking parameters were employed to perform the docking of each candidate ligand. From the docking results, the binding energy was obtained in the form of a grid score (kcal / mol) for each ligand to the receptor as presented in Table 6.

Fig 11. The cytotoxicities of Hydroxychloroquine (HCQ) and Lopinavir-Ritonavir (LOPIRITO) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of HCQ + LOPIRITO 8 µg/mL, LOPIRITO was added at a concentration of 8 µg/mL to each increased levels of HCQ i.e. 0.2, 2, 10, 100, and 400 µg/mL. On the other hand, HCQ was then added at a concentration of 6 µg/mL to each increased levels of LOPIRITO i.e. 0.2, 2, 10, 100, and 400 µg/mL to produce HCQ 6 µg/mL + LOPIRITO.

Discussion

The in vitro antiviral activities of dual combinatory drugs consisting of antiviral agents, i.e. LOPIRITO, FAVI, antibiotics such as AZI, CLA, DOXY, and HCQ against Vero cells infected with SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia were evaluated. These drugs have recently became the subject of interest for use in clinical trials, thereby providing information about their therapeutic effects as combinatory drugs within a highly effective strategy of providing pre-clinical evidence supporting their clinical use for combating pandemic COVID-19.

LOPIRITO is a protease inhibitor commonly employed in the treatment of HIV that, interestingly, has also been shown to have an antiviral effect on SARS-CoV and MERS-CoV by inhibiting the protease activity of coronavirus [17, 18, 32]. Within this study, its combined use with other drugs was evaluated. Significantly, most of these drug combinations demonstrated greater in vitro antiviral potency against the SARS-CoV-2 virus with lower cytotoxicity observed in mesenchymal stem cells than the single drug itself.

Fig 12. The photomicrographs of morphology changes of Vero cells before virus inoculation (A), at 24-h (B), 48-h (C), and 72-h (D) after virus inoculation observed at a magnification of 100x. The black arrow shows a giant cell formation and the white arrow indicates a cytopathic effect.

https://doi.org/10.1371/journal.pone.0252302.g012

The drug combinations were prepared in two ratio types, i.e. constant and non-constant weight ratios, due to the lack of data regarding the growth inhibition curves of these drugs in mesenchymal stem cells in addition to their IC_{50} values. Moreover, there is a paucity of information about which drug is more toxic to the cells and drug use in combination as evaluated in this study. This study aimed to identify the profile of drug interaction, whether synergistic,

Table 2. Virus titer of Vero cells infected with the SARS-CoV-2 virus isolates at a multiplicity of infection (MoI) of 0.04 at 24, 48, and 72 hours post infection.

Incubation period of viral infection	Virus Titer per μL
24 hours	12.10
48 hours	14.29
72 hours	38.19

https://doi.org/10.1371/journal.pone.0252302.t002

Table 3. The summary of antiviral activity (IC$_{50}$) of single and combination drugs against Vero cells infected with SARS-CoV-2 at an multiplicity of infection (MoI) value of 0.04.

Drugs	IC$_{50}$ (µg/mL)		
	24h	48h	72h
Lopinavir/Ritonavir (LOPIRITO)	12.10	<1.00	0.90
Azithromycin (AZI)	51.90	19.60	<10.00
Clarithromycin (CLA)	4.60	0.60	0.90
Doxycycline (DOXY)	18.00	4.70	0.40
Hydroxychloroquine (HCQ)	9.50	4.70	1.40
Favipiravir (FAVI)	9.60	18.60	<10.00
Lopinavir/Ritonavir + Azithromycin (LOPIRITO:AZI, 1:2)	<8.33	48.09	<8.33
Lopinavir/Ritonavir + Clarithromycin (LOPIRITO:CLA, 1:1)	6.90	3.90	<0.50
Lopinavir/Ritonavir + Doxycycline (LOPIRITO:DOXY, 1:1)	13.94	4.79	<2.50
Hydroxychloroquine + Azithromycin (HCQ:AZI, 1:2)	39.68	39.68	<16.66
Hydroxychloroquine + Doxycycline (HCQ:DOXY, 1:2)	30.80	<6.67	30.80
Favipiravir + Azithromycin (FAVI:AZI, 2:1)	48.46	14.53	86.99
Hydroxychloroquine + Favipiravir (HCQ:FAVI, 1:10)	57.72	74.77	<31.82
Hydroxychloroquine + Lopinavir/Ritonavir (HCQ:LOPIRITO, 1:2)	24.90	23.49	25.61

additional, or antagonistic, in order to establish their cytotoxic effect on mesenchymal stem cells. In principal, to obtain the appropriate ratio for clinical use, drug combinations were prepared at both constant and non-constant ratios, with their IC50 values being subsequently determined. After the profiles had been obtained, the constant ratio with low cytotoxicity was selected for further antiviral evaluation, while the non-constant ratio was not considered further. This was because the use of commercial products at a largely general dosage represents a more practical therapeutic application of COVID-19, not involving a customized dose or Fixed Dose Combination products.

LOPIRITO was combined with AZI, primarily used in the treatment of respiratory, enteric and genitourinary infection, which had also been recently employed as a therapeutic agent against COVID-19 infection [33]. In this study, the dual combination of LOPIRITO and AZI at respective ratios of 1:1 and 1:2 reduced the cytotoxicity of each single drug on mesenchymal stem cells. Moreover, their combination produced higher efficacy in reducing virus numbers, while also increasing IL-10 and reducing IL-6 and TNF-α levels.

LOPIRITO was also combined with CLA. Instead of monotherapy using only LOPIRITO, several hospitalized patients received CLA, a macrolide antibiotic, which inhibits protein synthesis in susceptible organisms (e.g. bacteria) by binding to the 50S ribosomal sub-unit [34]. The same results were also achieved by combining LOPIRITO and CLA at a weight ratio of 1:1. There was a decrease in cytotoxicity in normal cells and an increase of antiviral activity against SARS-CoV-2 virus compared with each single drug.

FAVI is an antiviral medication used to treat influenza in Japan which is also being evaluated for its effectiveness against other viral infections [35]. However, there is evidence that FAVI is teratogenic, with the result that considerable care needs to be exercised in avoiding its extensive use during pregnancy [36, 37]. AZI is a broad-spectrum macrolide antibiotic with a long half-life, excellent tissue penetration and a large distribution volume [9, 21]. DOXY is a broad-spectrum tetracycline-class antibiotic used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, early-stage Lyme disease, cholera, typhus, and syphilis [38]. HCQ is a medication used to prevent and treat malaria in areas where the disease remains resistant to chloroquine. Other

Fig 13. The efficacy (IC_{50}) evaluation of Lopinavir-Ritonavir (LOPIRITO), Favipiravir (FAVI), Azithromycin (AZI), Clarithromycin (CLA), Doxycycline (DOXY), and Hydroxychloroquine (HCQ) as a single drug in Vero cells infected with SARS-CoV-2 virus isolates for 24 hours (A), 48 hours (B), and 72 hours (C) analysed using CompuSyn Software at a multiplicity of infection (MoI) value of 0.04.

applications include the treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. HCQ is currently being studied to establish its efficacy in the prevention and treatment of COVID-19 [39].

The same results are also obtained by use of a combination of LOPIRITO + CLA (Fig 5), LOPIRITO + DOXY (Fig 6), HCQ + AZI (Fig 7), and HCQ + DOXY (Fig 8). These combinations showed the absence of cytotoxic effect in cells and viability exceeding 90%. The use of this combination provides a potential opportunity for antiviral testing due to its minimal toxic effects on mesenchymal cells.

Both FAVI and AZI, when administered as single drugs, and their combination (FAVI + AZI) produce extremely low cytotoxicity since they are relatively non-toxic to mesenchymal cells, as indicated by the high CC_{50} value, (see Fig 9). On the other hand, a drug combination of FAVI + HCQ has a higher CC_{50} value than HCQ as a single drug, which is relatively more toxic than FAVI, as can be seen from the contents of Fig 10. A combination of LOPIRITO + HCQ also has a higher CC_{50} value than HCQ as a single drug which is relatively more toxic than LOPIRITO, (see Fig 11).

Fig 14. The efficacy (IC$_{50}$) evaluation of dual combination of Lopinavir-Ritonavir (LOPIRITO), Azithromycin (AZI), Doxycycline (DOXY), Favipiravir (FAVI), Clarithromycin (CLA), and Hydroxychloroquine (HCQ) as a single drug in Vero cells infected with SARS-CoV-2 virus isolates for 24 hours (A), 48 hours (B), and 72 hours (C) analysed using CompuSyn Software at a multiplicity of infection (MoI) value of 0.04.

https://doi.org/10.1371/journal.pone.0252302.g014

Based on the CC$_{50}$ value data obtained, the application of a combination of LOPIRITO, AZI, CLA, DOXY, FAVI, and HCQ has the potential to reduce the degree of toxicity of the drug administered. Most drug combinations exhibit antagonistic effects which negate the side effects of other drugs. Thus, when viewed from the perspective of safety and toxicity, the potential use of a combination of therapeutic drugs, especially the treatment of COVID-19, is extremely high and can be considered effective. Furthermore, a virus challenge test was performed on a combination of drugs which was declared to be relatively safe.

Antiviral activity was assessed using Vero cells previously infected with SARS-CoV-2 isolates obtained from Universitas Airlangga Hospital. A summary of results can be seen in Table 3. It can be noted that the use of a single drug has the ability to reduce the amount of virus. The analysis involving the use of software can be seen in Fig 13. With a single drug, there was a decrease in the number of copies of the virus (Fa = number of copies of virus samples / positive controls) in accordance with the duration of drug incubation in the sample, whereby at 72 hours, almost all viruses in the test group had died. The antiviral activities of drug combinations can be seen in Fig 14 with a summary of the results contained in Table 4.

Table 4. The concentration of single and combination drugs (at a mass ratio) that produced an undetected virus copy number in the in vitro antiviral study against Vero cells infected with SARS-CoV-2 at a multiplicity of infection (MoI) value of 0.04 at 24, 48, and/or 72 hours' incubation.

Drugs	Drug concentration (µg/mL)	Results
Lopinavir/Ritonavir (LOPIRITO)	37.5	24, 48, 72h virus undetected
Azithromycin (AZI)	125	24, 48, 72h virus undetected
Clarithromycin (CLA)	8	24, 48, 72h virus undetected
Doxycycline (DOXY)	37.5	24, 48, 72h virus undetected
Hydroxychloroquine (HCQ)	37.5	48, 72h virus undetected
Favipiravir (FAVI)	37.5	24, 48, 72h virus still detected with decreasing number
Lopinavir/Ritonavir + Azithromycin (LOPIRITO:AZI, 1:2)	50	24, 48, 72h virus undetected
Lopinavir/Ritonavir + Clarithromycin (LOPIRITO:CLA, 1:1)	30	48, 72h virus undetected
Lopinavir/Ritonavir + Doxycycline (LOPIRITO:DOXY, 1:1)	25	24, 48, 72h virus undetected
Hydroxychloroquine + Azithromycin (HCQ:AZI, 1:2)	100	24, 48, 72h virus undetected
Hydroxychloroquine + Doxycycline (HCQ:DOXY, 1:2)	25	48, 72h virus undetected
Favipiravir + Azithromycin (FAVI:AZI, 2:1)	200	24, 48, 72h virus still detected with decreasing number
Hydroxychloroquine + Favipiravir (HCQ:FAVI, 1:10)	150	24, 48, 72h virus undetected
Hydroxychloroquine + Lopinavir/Ritonavir (HCQ:LOPIRITO, 1:2)	50	24, 48, 72h virus still detected with decreasing number

https://doi.org/10.1371/journal.pone.0252302.t004

The results indicate that drug combinations demonstrated greater effectiveness in reducing the amount of virus where IC_{50} values decreased after 24, 48 and 72 hours of the incubating of cells infected with the drug. As a combination drug, there was a decrease in the number of copies of the virus in some samples whereas, depending on the incubation time of the drug in the sample, there was a significant reduction in the amount of virus in the test group.

Table 5. The summary of the cytokine levels of Vero cells infected with SARS-CoV-2 isolates an multiplicity of infection (MoI) value of 0.04 at 24, 48, and 72 hours incubated with single and drug combinations. The data were in duplicates.

Drugs	IL-10	IL-6	TNF-α
Lopinavir/Ritonavir (LOPIRITO)	↗↗ (37.5 µg/mL; 72h)	↘↘ (15 µg/mL; 24, 48h)	No effects
Azithromycin (AZI)	↗↗ (15 µg/mL; 24h)	↘↘ (to 125 µg/mL; 24, 48, 72h)	No effects
Clarithromycin (CLA)	↗↗ (8 µg/mL; 48h)	↘↘ (1, 4, 8 µg/mL; 24, 48, 72h)	No effects
Doxycycline (DOXY)	↗↗ (1 µg/mL; 48, 72h)	↘↘ (1 µg/mL; 24h)	↘↘ (1 µg/mL; 24h)
Hydroxychloroquine (HCQ)	↗↗ (15 µg/mL; 48h)	↘↘ (1 µg/mL; 24h)	No effects
Favipiravir (FAVI)	↗↗ (10, 15 µg/mL; 48, 72h)	↘↘ (to 100 µg/mL; 48h)	↘↘ (10 ppm; 24h)
Lopinavir/Ritonavir + Azithromycin (LOPIRITO:AZI, 1:2)	↗↗ (25, 50, 100 µg/mL; 48,72h) → strong	↘↘ (and IL-2) (25, 50, 100 µg/mL; 24, 48, 72h) → strong IL-2: ↘↘ (100 µg/mL; 24, 48h)	↘↘ (25 ppm; 24h)
Lopinavir/Ritonavir + Clarithromycin (LOPIRITO:CLA, 1:1)	↗↗ (1, 10 µg/mL; 24, 48, 72h)	↘↘ (1 µg/mL; 24, 48h)	↘↘ (30 µg/mL; 24, 48, 72h)
Lopinavir/Ritonavir + Doxycycline (LOPIRITO:DOXY, 1:1)	↗↗ (5, 10 µg/mL; 48, 72h)	↘↘ (and IL-2) (10, 25 µg/mL; 48h) → strong IL-2: ↘↘ (5, 10 µg/mL; 48, 72 h)	↘↘ (5, 10, 25 µg/mL; 24, 48, 72h) → strong
Hydroxychloroquine + Azithromycin (HCQ:AZI, 1:2)	↗↗ (25,50 µg/mL; 48,72h)	↘↘ (and IL-2) (25, 50, 100 µg/mL; 24, 48, 72h) → strong	↘↘ (25 µg/mL; 24h)
Hydroxychloroquine + Doxycycline (HCQ:DOXY, 1:2)	↗↗ (25 µg/mL; 24, 48, 72h)	No effects	↘↘ (10, 25, 50 µg/mL; 24, 48, 72h)
Favipiravir + Azithromycin (FAVI:AZI, 2:1)	No effects	No effects	No effects
Hydroxychloroquine + Favipiravir (HCQ:FAVI, 1:10)	No effects	↘↘ (35, 75 µg/mL; 24h)	No effects
Hydroxychloroquine + Lopinavir/Ritonavir (HCQ:LOPIRITO, 1:2)	↗↗ (25, 50 µg/mL; 48h)	↘↘ (25, 50 µg/mL; 48h)	No effects

Note: (25, 50 µg/mL; 48h) means that at concentration of 25 and 50 µg/mL of drug combination, the changes in interleukin levels were observed at48 hours post incubation. ↗↗: increased, ↘↘: decreased.

https://doi.org/10.1371/journal.pone.0252302.t005

Fig 15. The molecular structures of native ligand binding to receptor in SARS-CoV-2.

An analysis of pro-inflammatory and anti-inflammatory responses was conducted, including Interleukin-10 (IL-10), Interleukin-6 (IL-6), and Tumor Necrosis Factor-α (TNF-α). From the results presented in Table 5, the majority of drug administration increased IL-10 levels as an anti-inflammatory marker and reduced IL-6 and TNF-α levels as pro-inflammatory markers. Only in the combination of FAVI + AZI (2:1) was the effect negligible. The interactions observed in this study can be physical or chemical and affect the ability of the drugs to infiltrate the cell to cause further toxic effects and inhibit or reduce the rate of viral infectivity in host cells.

Molecular docking was employed to predict interactions between ligands and protein. The interaction can be seen from the binding site of the macromolecular target. The docking process consists of two interrelated stages, docking algorithm and scoring function. The

Table 6. The docking scores of potential SARS-CoV-2 main protease inhibitor drug.

No	Chemical Name	Molecular Weight (g/mol)	Docking Score (kcal/mol)
1	Lopinavir (LOPI, $C_{37}H_{48}N_4O_5$)	628.8	-28.56
2	Ritonavir (RITO, $C_{37}H_{48}N_6O_5S_2$)	720.9	-30.47
3	Favipiravir (FAVI, $C_5H_4FN_3O_2$)	157.1	-23.11
4	Azithromycin (AZI, $C_{38}H_{72}N_2O_{12}$)	749	-22.01
5	Clarithromycin (CLA, $C_{38}H_{69}NO_{13}$)	748	-25.48
6	Doxycycline (DOXY, $C_{22}H_{24}N_2O_8$)	444.4	-37.46
7	Hydroxychloroquine (HCQ, $C_{18}H_{26}ClN_3O$)	335.9	-29.59

docking algorithm obtains the most stable conformation of the ligand-protein complex formed. Molecular bonds will be formed from functional groups of ligands that interact with residues of amino acid receptor proteins. The scoring function is intended to evaluate conformation by calculating the strength of the affinity between ligand and protein and then directing the exploration of the ligand conformation to a position with a stronger affinity [40]. The affinity value obtained was in the form of Gibbs free energy. A low Gibbs free energy value indicates that the conformation formed is stable, while a high one indicates the formation of a less stable complex. The more negative the value produced, the stronger the affinity of the ligand-protein complex, with the result that its activity is expected to be of even higher quality [41, 42].

The SARS-CoV-2 main protease (PDB ID: ALU6) is a ~306 amino acid long main protease whose crystal structure with a resolution of 1.93 Å has been elucidated. The main protease enzyme is the optimum target for inhibiting the SARS-CoV-2 virus. This protease breaks the spikes and is further established by penetration. This study was undertaken to identify possible compounds that can bind to the main protease which may be used as a potential drug for SARS-CoV-2. The results indicated that all the ligands, i.e. LOPI, RITO, FAVI, AZI, CLA, DOXY, and HCQ, can bind with the main protease with a high docking score of -37.46 to -22.01 kcal/mol (see Table 6). It is probable that the compounds inhibit the process of viral replication and translation and may have an extremely significant impact on controlling the viral load in infected individuals.

Conclusion

Using a combination of drugs would reduce the degree of cytotoxicity compared to a single drug, increase antiviral activity, and produce a lower effect on pro-inflammatory markers and intensify anti-inflammatory response. Hence, it can reduce the toxic potency in cells and increase the effectiveness with regard to reducing the number of copies of the SARS-CoV-2 virus. Based on the degree of therapeutic effectiveness, toxicity in vitro, and response to inflammatory markers, the activity of a single drug from the highest to the lowest is as follows: CLA > LOPIRITO > DOXY > AZI > HCQ.

Based on the degree of therapeutic effectiveness, toxicity in vitro, and the response to inflammatory markers, the activity of a drug combination ranging from the highest to lowest is the following: LOPIRITO + AZI > LOPIRITO + AZI > HCQ + AZI > HCQ + FAVI > LOPIRITO + CLA > HCQ + DOXY. However, further studies are required regarding the possible interactions.

Supporting information

S1 Table. The cytotoxicity data of combinatory drugs on mesenchymal human stem cells.
(PDF)

S2 Table. The average virus titer of Vero cells infected with SARS-CoV-2 isolates an multiplicity of infection (MoI) value of 0.04 at 24, 48, and 72 hours incubated with single and drug combinations (n = 2).
(PDF)

S3 Table. The cytokine levels of Vero cells infected with SARS-CoV-2 isolates an multiplicity of infection (MoI) value of 0.04 at 24, 48, and 72 hours incubated with single and drug combinations (n = 2).
(PDF)

Acknowledgments

Author Contributions

Conceptualization: Purwati, Andang Miatmoko.

Data curation: Andang Miatmoko, Eryk Hendrianto, Deya Karsari, Aristika Dinaryanti, Nora Ertanti, Igo Syaiful Ihsan, Tri Pudy Asmarawati, Erika Marfiani, Alfian Nur Rosyid, Prastuti Asta Wulaningrum, Herley Windo Setiawan, Imam Siswanto, Ni Nyoman Tri Puspaningsih.

Formal analysis: Andang Miatmoko, Nasronudin, Deya Karsari, Aristika Dinaryanti, Nora Ertanti, Igo Syaiful Ihsan, Tri Pudy Asmarawati, Erika Marfiani, Yulistiani, Imam Siswanto, Ni Nyoman Tri Puspaningsih.

Funding acquisition: Purwati.

Investigation: Nasronudin, Eryk Hendrianto, Deya Karsari, Aristika Dinaryanti, Nora Ertanti, Igo Syaiful Ihsan, Tri Pudy Asmarawati, Erika Marfiani, Alfian Nur Rosyid, Prastuti Asta Wulaningrum, Herley Windo Setiawan, Imam Siswanto, Ni Nyoman Tri Puspaningsih.

Methodology: Purwati, Andang Miatmoko, Eryk Hendrianto, Igo Syaiful Ihsan, Tri Pudy Asmarawati, Erika Marfiani, Imam Siswanto, Ni Nyoman Tri Puspaningsih.

Project administration: Eryk Hendrianto, Deya Karsari, Aristika Dinaryanti, Nora Ertanti, Igo Syaiful Ihsan.

Resources: Purwati, Nora Ertanti, Disca Sandyakala Purnama.

Software: Purwati, Imam Siswanto, Ni Nyoman Tri Puspaningsih.

Supervision: Purwati, Andang Miatmoko, Nasronudin, Igo Syaiful Ihsan, Tri Pudy Asmarawati, Erika Marfiani, Alfian Nur Rosyid, Prastuti Asta Wulaningrum, Herley Windo Setiawan.

Validation: Purwati, Andang Miatmoko, Tri Pudy Asmarawati, Erika Marfiani, Yulistiani, Alfian Nur Rosyid, Prastuti Asta Wulaningrum, Herley Windo Setiawan.

Visualization: Purwati, Andang Miatmoko, Disca Sandyakala Purnama, Tri Pudy Asmarawati, Erika Marfiani, Prastuti Asta Wulaningrum, Herley Windo Setiawan.

Writing – original draft: Purwati, Andang Miatmoko, Disca Sandyakala Purnama, Imam Siswanto, Ni Nyoman Tri Puspaningsih.

Writing – review & editing: Purwati, Andang Miatmoko, Imam Siswanto, Ni Nyoman Tri Puspaningsih.

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264

2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224): 565–74. https://doi.org/10.1016/S0140-6736(20)30251-8 PMID: 32007145

3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382: 727–733. https://doi.org/10.1056/NEJMoa2001017 PMID: 31978945

4. Manusubroto W, Wicaksono AS, Tamba DA, Sudiharto P, Pramusinto H, Hartanto RA, et al. Neurosurgery services in Dr. Sardjito General Hospital, Yogyakarta, Indonesia, during COVID-19 pandemic: an experience from a developing country. World Neurosurg. 2020; 140: e360–e366. https://doi.org/10.1016/j.wneu.2020.05.124 PMID: 32442732

5. Dayer MR, Taleb-Gassabi S, Dayer MS. Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study. Arch Clin Infect Dis. 2017; 12(4): e13823.

6. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1): 58–60. https://doi.org/10.5582/ddt.2020.01012 PMID: 32147628

7. Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7(1): 4. https://doi.org/10.1186/s40779-020-0233-6 PMID: 32029004

8. AbbVie Deutschland GmbH & Co. KG. AluviaH-W-764: Summary of Product Characteristics. European Medicines Agency, Germany; 2020 [cited 15 March 2021]. Available from: https://www.ema.europa.eu/en/aluvia-h-w-764

9. Singlas E. [Clinical pharmacokinetics of azithromycin]. Pathol Biol (Paris). 1995 Jun; 43(6): 505–11.

10. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Drug Dispos. 1993; 25 (3): 189–204. https://doi.org/10.2165/00003088-199325030-00003 PMID: 8222460

11. Newton PN, Brockman A, Chierakul W, Dondorp A, Ruangveerayuth R, Looareesuwan S, et al. Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrob Agents Chemother. 2005; 49(4): 1622–5. https://doi.org/10.1128/AAC.49.4.1622-1625.2005 PMID: 15793155

12. Lim H, Im J, Cho J, Bae K, Klein TA, Yeom J, et al. Pharmacokinetics of Hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax. Antimicrob Agents Chemother. 2009; 53(4): 1468–75. https://doi.org/10.1128/AAC.00339-08 PMID: 19188392

13. Taisho Toyama Pharmaceutical. Avigan Tablets 200 mg. 2017 [cited 15 March 2021]. Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw.

14. Retallack H, Di E, Arias C, Knopp KA, Laurie MT. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. PNAS. 2016; 113(50): 14408–12. https://doi.org/10.1073/pnas.1618029113 PMID: 27911847

15. Dayer MR. Old drugs for newly emerging viral disease, COVID-19: bioinformatic prospective. arXiv:2003.04524 [Preprint]. 2020 [cited 7 March 2021]. Available from: https://arxiv.org/abs/2003.04524

16. Arabi YM, Deeb AM, Al-hameed F, Mandourah Y, Almekhla GA, Sindi AA, et al. Macrolides in critically ill patients with middle east respiratory syndrome. Int J Infect Dis. 2019; 81: 184–90. https://doi.org/10.1016/j.ijid.2019.01.041 PMID: 30690213

17. Rothan HA, Mohamed Z. Inhibitory effect of doxycycline against dengue virus replication in vitro. Arch Virol. 2014; 159: 711–8. https://doi.org/10.1007/s00705-013-1880-7 PMID: 24142271

18. Liu X, Wan X-J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020; 47: 119–21. https://doi.org/10.1016/j.jgg.2020.02.001 PMID: 32173287

19. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2016; 314(19): 2034–44.

20. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020; 2020: 55(4): 105945. https://doi.org/10.1016/j.ijantimicag.2020.105945 PMID: 32194152

21. Devaux CA, Rolain J, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020; 55(5): 105938. https://doi.org/10.1016/j.ijantimicag.2020.105938 PMID: 32171740

22. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Antiviral effects of chloroquine: Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3(11): 722–7. https://doi.org/10.1016/s1473-3099(03)00806-5 PMID: 14592603

23. Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY). 2020; 12(8): 6511–6517. https://doi.org/10.18632/aging.103001 PMID: 32229706

24. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3): 252–6. https://doi.org/10.1136/thorax.2003.012658 PMID: 14985565

25. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020; 582(7811): 289–93. https://doi.org/10.1038/s41586-020-2223-y PMID: 32272481

26. Wang Z, Sun H, Yao X, Li D, Xu L, Li Y, et al. Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: The prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys. 2016; 18(18): 12964–75. https://doi.org/10.1039/c6cp01555g PMID: 27108770

27. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J Chem Theory Comput. 2015; 11(8): 3696–713. https://doi.org/10.1021/acs.jctc.5b00255 PMID: 26574453

28. Allen WJ, Balius TE, Mukherjee S, Brozell SR, Moustakas DT, Lang PT, et al. DOCK 6: Impact of new features and current docking performance. J Comput Chem. 2015; 36(15): 1132–56. https://doi.org/10.1002/jcc.23905 PMID: 25914306

29. Covas D, Siufi J, Silva A, Orellana M. Isolation and culture of umbilical vein mesenchymal stem cells. Brazilian J Med Biol Res. 2003; 36(9): 1179–83. https://doi.org/10.1590/s0100-879x2003000900006 PMID: 12937783

30. Lu L, Liu Y-J, Yang S-G, Zhao Q, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006; 91(8): 1017–26. PMID: 16870554

31. Mennan C, Wright K, Bhattacharjee A, Balain B, Richardson J, Roberts S. Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed Res Int. 2013; 2013: 1–8. https://doi.org/10.1155/2013/916136 PMID: 23984420

32. Chan JF-W, Yao Y, Yeung M-L, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015; 212(12): 1904–13. https://doi.org/10.1093/infdis/jiv392 PMID: 26198719

33. Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther. 2020; 108(2): 201–211. https://doi.org/10.1002/cpt.1857 PMID: 32302411

34. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020; 323(24): 2493–2502. https://doi.org/10.1001/jama.2020.8630 PMID: 32392282

35. Dinos GP. The macrolide antibiotic renaissance. Br J Pharmacol. 2017; 174: 2967–83. https://doi.org/10.1111/bph.13936 PMID: 28664582

36. Du Y, Chen X. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020; 108(2): 242–247. https://doi.org/10.1002/cpt.1844 PMID: 32246834

37. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020; 76(4):370–376. https://doi.org/10.1016/j.mjafi.2020.08.004 PMID: 32895599

38. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015; 314(19): 2034–44. https://doi.org/10.1001/jama.2015.13896 PMID: 26575060

39. Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011; 1241: 17–32. https://doi.org/10.1111/j.1749-6632.2011.06354.x PMID: 22191524

40. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan M V, et al. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J. 2020; 34(5): 6027–37. https://doi.org/10.1096/fj.202000919 PMID: 32350928

41. Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011; 7(2): 146–57. https://doi.org/10.2174/157340911795677602 PMID: 21534921

42. Du X, Li Y, Xia Y, Ai S, Liang J, Sang P, et al. Insights into protein–ligand interactions: mechanisms, models, and methods. Int J Mol Sci. 2016; 17(144): 1–34.

SJR Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

Home   Journal Rankings   Country Rankings   Viz Tools   Help   About Us

PLoS ONE 🔓

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United States	Multidisciplinary Multidisciplinary	Public Library of Science	**367**
🏛 Universities and research institutions in United States			

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	19326203	2001, 2006-2021	Homepage
			How to publish in this journal
			plosone@plos.org

SCOPE

PLOS ONE welcomes original research submissions from the natural sciences, medical research, engineering, as well as the related social sciences and humanities, including: -Primary research that contributes to the base of scientific knowledge, including interdisciplinary, replication studies, and negative or null results. -Systematic reviews whose methods ensure the comprehensive and unbiased sampling of existing literature. -Submissions describing methods, software, databases, or other tools that meet the journal's criteria for utility, validation and availability. -Qualitative research that adheres to appropriate study design and reporting guidelines.

∨

◯ Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS ❓

1	2	3	4
PeerJ	**BMC Research Notes**	**Scientific Reports**	**Molecular Biolog**
USA	GBR	GBR	NLD
76%	**73%**	**72%**	**69**
similarity	similarity	similarity	simila

SJR

3

2

1

0

2007 2009 2011 2013 2015 2017 2019 2021

Total Documents

40k

20k

0

2001 2004 2007 2010 2013 2016 2019

Total Cites   Self-Cites

400k

200k

0

2001 2004 2007 2010 2013 2016 2019

Citations per document

External Cites per Doc   Cites per Doc

6

6

% International Collaboration

120

80

40

0

2001 2004 2007 2010 2013 2016 2019

Citable documents **Non-citable documents**

100k

50k

0

2001 2004 2007 2010 2013 2016 2019

Cited documents **Uncited documents**

100k

50k

0

2001 2004 2007 2010 2013 2016 2019

PLoS ONE

Q1 | Multidisciplinary

best quartile

SJR 2021
0.85

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

`<a href="https://www.scima`

G SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of April 2022

A **Abera** 6 months ago

I have published my first paper in plos one and it is fast as it lasts only 3 months interval. However, for my second paper be come to late that means 6 months. How we can speed up to publication?

reply

SCImago Team

Scopus

🔍 ☰

Source details

PLoS ONE

Open Access ⓘ

Scopus coverage years: from 2006 to Present

Publisher: Public Library of Science

ISSN: 1932-6203

Subject area: (Multidisciplinary)

Source type: Journal

| View all documents > | Set document alert | 💾 Save to source list | Source Homepage |

CiteScore 2021
5.6   ⓘ

SJR 2021
0.852   ⓘ

SNIP 2021
1.368   ⓘ

CiteScore   CiteScore rank & trend   Scopus content coverage

⤴ Export content for category

CiteScore rank ⓘ 2021 ⌄   In category: Multidisciplinary   🔄 Loading...

| | #15 ── 120 | PLoS ONE | 5.6 | 87th percentile |

☆	Rank	Source title	CiteScore 2021	Percentile
☆	#1	Nature	70.2	99th percentile
☆	#2	Science	57.8	98th percentile
☆	#3	Nature Communications	23.2	97th percentile
☆	#4	National Science Review	19.1	97th percentile
☆	#5	Science advances	18.5	96th percentile
☆	#6	Proceedings of the National Academy of Sciences of the United States of America	18.1	95th percentile
☆	#7	Science Bulletin	17.2	94th percentile
☆	#8	Journal of Advanced Research	17.1	93rd percentile
☆	#9	Research	10.5	92nd percentile
☆	#10	The Innovation	10.0	92nd percentile
☆	#11	Scientific Reports	6.9	91st percentile

CiteScore trend

	Rank	Source title	CiteScore 2021	Percentile
☆	#12	Tsinghua Science and Technology	5.8	90th percentile
☆	#13	Royal Society Open Science	5.7	89th percentile
☆	#14	iScience	5.7	88th percentile
☆	#15	PLoS ONE	5.6	87th percentile
☆	#16	Advanced Theory and Simulations	5.5	87th percentile
☆	#17	Journal of King Saud University - Science	5.3	86th percentile
☆	#18	Emerging Science Journal	5.2	85th percentile
☆	#19	Karbala International Journal of Modern Science	4.7	84th percentile
☆	#20	Journal of the Royal Society of New Zealand	4.5	83rd percentile
☆	#21	Arabian Journal for Science and Engineering	4.4	82nd percentile
☆	#22	Heliyon	4.0	82nd percentile
☆	#23	International Journal of Bifurcation and Chaos in Applied Sciences and Engineering	4.0	81st percentile
☆	#24	Transactions of Tianjin University	3.7	80th percentile
☆	#25	Complexity	3.5	79th percentile
☆	#26	Applied Network Science	3.5	78th percentile
☆	#27	Facets	3.4	77th percentile
☆	#28	International Journal of Agile Systems and Management	3.3	77th percentile
☆	#29	International Journal of Service Science, Management, Engineering, and Technology	3.2	76th percentile
☆	#30	Journal of the Indian Institute of Science	2.9	75th percentile
☆	#31	Science, Technology and Society	2.6	74th percentile
☆	#32	Anais da Academia Brasileira de Ciencias	2.5	73rd percentile
☆	#33	Scientific African	2.4	72nd percentile
☆	#34	Data in Brief	2.4	72nd percentile
☆	#35	Sadhana - Academy Proceedings in Engineering Sciences	2.3	71st percentile
☆	#36	Citizen Science: Theory and Practice	2.2	70th percentile

	Rank	Source title	CiteScore 2021	Percentile
☆	#37	Foundations of Science	2.1	69th percentile
☆	#38	Kexue Tongbao/Chinese Science Bulletin	1.9	68th percentile
☆	#39	Pacific Science	1.8	67th percentile
☆	#40	Sains Malaysiana	1.8	67th percentile
☆	#41	Journal of Mathematical and Fundamental Sciences	1.7	66th percentile
☆	#42	Current Science	1.6	65th percentile
☆	#43	Kuwait Journal of Science	1.6	64th percentile
☆	#44	Universitas Scientiarum	1.6	63rd percentile
☆	#45	Springer Handbooks	1.6	62nd percentile
☆	#46	Perspectives on Science	1.6	62nd percentile
☆	#47	Latin American Research Review	1.5	61st percentile
☆	#48	Journal of Scientific and Industrial Research	1.4	60th percentile
☆	#49	Journal of Shanghai Jiaotong University (Science)	1.4	59th percentile
☆	#50	Fundamental Research	1.4	58th percentile
☆	#51	World Review of Science, Technology and Sustainable Development	1.3	57th percentile
☆	#52	Journal of the National Science Foundation of Sri Lanka	1.3	57th percentile
☆	#53	Tapuya: Latin American Science, Technology and Society	1.3	56th percentile
☆	#54	Journal of the Royal Society of Western Australia	1.3	55th percentile
☆	#55	Brazilian Archives of Biology and Technology	1.3	54th percentile
☆	#56	Science Progress	1.2	53rd percentile
☆	#57	Xinan Jiaotong Daxue Xuebao/Journal of Southwest Jiaotong University	1.1	52nd percentile
☆	#58	Gazi University Journal of Science	1.1	52nd percentile
☆	#59	Maejo International Journal of Science and Technology	1.1	51st percentile
☆	#60	Historia Agraria	1.1	50th percentile
☆	#61	ScienceAsia	1.0	49th percentile

	Rank	Source title	CiteScore 2021	Percentile
☆	#62	Jilin Daxue Xuebao (Gongxueban)/Journal of Jilin University (Engineering and Technology Edition)	1.0	48th percentile
☆	#63	Tongji Daxue Xuebao/Journal of Tongji University	0.9	47th percentile
☆	#64	Tianjin Daxue Xuebao (Ziran Kexue yu Gongcheng Jishu Ban)/Journal of Tianjin University Science and Technology	0.9	47th percentile
☆	#65	Beijing Daxue Xuebao (Ziran Kexue Ban)/Acta Scientiarum Naturalium Universitatis Pekinensis	0.9	46th percentile
☆	#66	Songklanakarin Journal of Science and Technology	0.9	45th percentile
☆	#67	Movement and Sports Sciences - Science et Motricite	0.9	44th percentile
☆	#68	Hunan Daxue Xuebao/Journal of Hunan University Natural Sciences	0.9	43rd percentile
☆	#69	Journal of Applied Science and Engineering (Taiwan)	0.9	42nd percentile
☆	#70	Interciencia	0.9	42nd percentile
☆	#71	Wuhan University Journal of Natural Sciences	0.9	41st percentile
☆	#72	AAS Open Research	0.9	40th percentile
☆	#73	Philippine Journal of Science	0.8	39th percentile
☆	#74	Malaysian Journal of Science	0.8	38th percentile
☆	#75	Walailak Journal of Science and Technology	0.8	37th percentile
☆	#76	International Journal of Innovative Research and Scientific Studies	0.8	37th percentile
☆	#77	Vibroengineering Procedia	0.7	36th percentile
☆	#78	Archives des Sciences	0.7	35th percentile
☆	#79	Journal of Sciences, Islamic Republic of Iran	0.7	34th percentile
☆	#80	Comptes Rendus de L'Academie Bulgare des Sciences	0.7	33rd percentile
☆	#81	Shanghai Jiaotong Daxue Xuebao/Journal of Shanghai Jiaotong University	0.7	32nd percentile
☆	#82	Bulletin of the Georgian National Academy of Sciences	0.7	32nd percentile
☆	#83	International Journal of Language and Culture	0.7	31st percentile
☆	#84	Constructivist Foundations	0.6	30th percentile

	Rank	Source title	CiteScore 2021	Percentile
☆	#85	Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences	0.6	29th percentile
☆	#86	Psychotherapy and Politics International	0.6	28th percentile
☆	#87	Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)/Journal of Xi'an Shiyou University, Natural Sciences Edition	0.6	27th percentile
☆	#88	Papers and Proceedings - Royal Society of Tasmania	0.6	27th percentile
☆	#89	Shenyang Jianzhu Daxue Xuebao (Ziran Kexue Ban)/Journal of Shenyang Jianzhu University (Natural Science)	0.6	26th percentile
☆	#90	ASM Science Journal	0.5	25th percentile
☆	#91	Bulletin de la Societe Royale des Sciences de Liege	0.5	24th percentile
☆	#92	Ohio Journal of Sciences	0.5	23rd percentile
☆	#93	Scientific American	0.5	22nd percentile
☆	#94	Science and Technology Asia	0.5	22nd percentile
☆	#95	Zhongshan Daxue Xuebao/Acta Scientiarum Natralium Universitatis Sunyatseni	0.5	21st percentile
☆	#96	Journal of Zhejiang University, Science Edition	0.4	20th percentile
☆	#97	Science, Engineering and Health Studies	0.4	19th percentile
☆	#98	Acta Scientiae	0.4	18th percentile
☆	#99	Transdisciplinary Journal of Engineering and Science	0.4	17th percentile
☆	#100	Mindanao Journal of Science and Technology	0.4	17th percentile
☆	#101	Metode	0.4	16th percentile
☆	#102	Liaoning Gongcheng Jishu Daxue Xuebao (Ziran Kexue Ban)/Journal of Liaoning Technical University (Natural Science Edition)	0.4	15th percentile
☆	#103	Journal and Proceedings - Royal Society of New South Wales	0.3	14th percentile
☆	#104	Journal of Current Science and Technology	0.3	13th percentile
☆	#105	International Journal of Systematic Innovation	0.3	12th percentile
☆	#106	Know	0.3	12th percentile
☆	#107	Revista Lasallista de Investigacion	0.3	11th percentile

	Rank	Source title	CiteScore 2021	Percentile
☆	#108	Chinese Annals of History of Science and Technology	0.2	10th percentile
☆	#109	Scientific Journal of King Faisal University Basic and Applied Sciences	0.2	9th percentile
☆	#110	Proceedings of Science	0.2	8th percentile
☆	#111	New Scientist	0.2	7th percentile
☆	#112	European Journal of Interdisciplinary Studies	0.2	7th percentile
☆	#113	Revista Conhecimento Online	0.1	6th percentile
☆	#114	International Journal of Advanced and Applied Sciences	0.1	5th percentile
☆	#115	Radovi Zavoda za Znanstvenoistrazivacki i Umjetnicki Rad u Bjelovaru	0.1	4th percentile
☆	#116	Edelweiss Applied Science and Technology	0.1	3rd percentile
☆	#117	Advanced Topics in Science and Technology in China	0.1	2nd percentile
☆	#118	Trends in Sciences	0.0	2nd percentile
☆	#119	Israa University Journal of Applied Science	0.0	0th percentile
☆	#119	Taiwan Review	0.0	0th percentile

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語版を表示する

查看简体中文版本

查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help

Tutorials

Contact us